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Zusammenfassung 
Thyroxin-Rezeptoren (TR) sind liganden-abhängige Transkriptionsfaktoren, 
die die Erythropoese beeinflussen. In dieser Arbeit wurde die TR-Aktivität in 
erythroiden Zellen mittels genomweiter Genexpressionsanalysen bestimmt. Der 
durch Thyroxin (T3) aktivierte TR beschleunigt die Differenzierung von 
erythroiden Vorläuferzellen und inhibierte die Proliferation dieser Zellen. 
Daher wurden erythroide Vorläuferzellen mit Erythropoietin (Epo) und 
Insulin in vitro mit und ohne T3 differenziert.  
Der Vergleich dieser beiden Expressionsprofile zeigte, dass Gene, die zur 
Differenzierung beitragen, schneller reguliert wurden, wenn die Zellen mit T3 
behandelt wurden; hierzu zählen GATA-2, c-kit und Band 3. Darüber hinaus 
wurden Gene reguliert, denen bisher noch keine bekannte Funktion während 
der erythroiden Differenzierung zugeschrieben werden konnte. Dazu gehören 
BTEB1 (“basic transcription factor 1/Krüppel-like factor 9”) und GAR22 
(“growth arrest specific gene 2 on chromosome 22”). Darüber hinaus wurde 
gefunden, dass die Expression des GAR22-Gens direkt durch TR reguliert 
wird. GAR22 wurde ursprünglich als potenzielles Tumorsuppressor-Gen 
identifiziert und kann somit Zellproliferation und Zellzyklus beeinflussen. In 
dieser Arbeit konnte ich zeigen, dass GAR22 den Zellzyklus von erythroiden 
Vorläuferzellen verlängert, aber keinen Einfluss auf die Expression von 
erythroiden Genen hat.  
GAR22 bindet an die Cytoskelett-Strukturen der Mirkotubuli und 
Mikrofilamente. GAR22 könnte daher eine Rolle bei den Veränderungen des 
Cytoskeletts spielen, welche während der erythroiden Zelldifferenzierung 
ablaufen. Um die Rolle von GAR22 im Cytoskelett näher zu untersuchen, 
wurden verschiedene Grün-Fluoreszenz-Protein (GFP)-gekopplete GAR22-
Fusionsproteine generiert. Die Lokalisierung und Dynamik von GAR22 wurde 
anschließend in B16F1 Mausmelanoma-Zellen und NIH3T3 Fibroblasten 
beobachtet. Diese Zellen sind aufgrund ihrer flachen und adhärenten 
Morphologie sowie ihrer ausgeprägter Mobilität ein geeignetes experimentelles 
System, um das Cytoskelett und die Zellmigration zu studieren.  
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GAR22 wird von der Zelle in zwei Speißvarianten generiert: GAR22α und 
GAR22β. Beide GAR22 Varianten binden an Aktin und folgen der Dynamik 
von Aktin, was darauf hinweist, dass GAR22 an der Regulation des Aktin-
Cytoskeletts und der Zellmigration beteiligt sein könnte. Diese Hypothese 
konnte mit der Beobachtung bestätigt werden, dass GAR22β 
überexprimierende Zellen in der gerichteten Zellbewegung eingeschränkt sind. 
Um die Funktion von GAR22 weiter zu charakterisieren, wurde mittels 
Proteomiktechnologien und Massenspektrometrie GAR22-bindende Proteine 
gesucht. Dies führte zu der Identifikation von EB1 (“end binding protein 1”) 
als neuer Interaktionspartner von GAR22β. Diese Bindung wird über den 
Carboxy-terminalen Teil von GAR22β vermittelt.  
EB1 bindet an die Plus-Enden der Mikrotubuli, wodurch es die Dynamik und 
Stabilität der Mikrotubuli reguliert. Die Interaktion von GAR22β und EB1 
könnte die Mikrotubulidynamik beeinflussen. Diese Annahme wird durch die 
Beobachtung unterstützt, dass in GAR22β exprimierenden Zellen, EB1 nicht 
mehr an den Plus-Enden der Mikrotubuli lokalisiert ist. Das geht mit dem 
Zusammenbruch der Mikrotubulistruktur einher. Desweiteren sind diese Zellen 
nicht in der Lage, ihr Mikrotubuli-Cytoskelett im selben Zeitrahmen 
wiederherzustellen wie nicht-transfizierte Kontrollzellen.  
Um die Bedeutung der Interaktion von GAR22β mit Mikrofilamenten und 
Mikrotubuli weiter zu untersuchen, wurden die Aktin-Bindedomäne oder die 
Mikrotubuli-Bindedomäne von GAR22β jeweils selektiv deletiert. Zellen, die 
eine der beiden Mutanten überexprimierten, zeigten eine erhöhte 
Zellmigration, im Gegensatz zu Zellen, die das nicht-mutierte GAR22β 
exprimierten. Diese Ergebnisse weisen darauf hin, dass GAR22β die gerichtete 
Zellbewegung durch die Regulation der EB1-Mikrotubuli Bindung, beeinflusst. 
Durch die duale Bindung von GAR22 an Mikrofilamenten und Mikrotubuli 
kann GAR22β das funktionelle Zusammenspiel der beiden Cytoskelette 
regulieren. Zusammenfassend konnte gezeigt werden, dass die Aktivität von 
GAR22β in der Zellbewegung von entscheidender Rolle ist und die Funktion 
von GAR22β über die in der Erythropoese hinausgeht. 
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Summary 
Thyroid hormone receptors (TRs) are ligand-dependent transcription factors 
that have a major impact on erythroid cell development. In this study, I have 
investigated the influence of TR activity on red blood cell gene expression and 
identified TR target genes by employing a genome-wide approach with DNA 
microarray. 
Ligand-activated TR potently accelerated differentiation of SCF/Epo-
dependent progenitors in vitro, concomitantly with inducing growth arrest. 
By comparing the gene expression profile of untreated and T3 treated 
SCF/Epo progenitor cells, I demonstrated that T3 potently regulated a 
subset of genes involved in erythroid differentiation, such as GATA-2, c-kit 
and Band 3. Furthermore, T3 regulated genes previously not implicated in 
differentiation of erythroid cells, including BTEB1 (basic transcription 
binding protein 1/ Krüppel-like factor 9) and the novel TR target gene 
GAR22 (growth arrest specific gene 2 on chromosome 22). The upregulation 
of GAR22 in terminally differentiated cells suggests that GAR22 might be 
involved in regulation of growth control and cell cycle. Accordingly, ectopic 
expression of GAR22 in SCF/Epo progenitor cells lengthened the cell cycle, 
but did not affect red cell gene expression. This finding is consistent with the 
proposed role of GAR22 as a tumor suppressor.  
GAR22 binds to microtubules and microfilaments, and this might contribute 
to the intense cytoskeletal remodeling that takes place during red blood cell 
differentiation. To investigate GAR22 binding to microfilaments and 
microtubules, I generated a panel of green fluorescent protein (GFP)-tagged 
GAR22 fusion proteins. For studying GAR22 dynamics, B16F1 mouse 
melanoma cells and NIH3T3 fibroblasts were chosen, since they have a flat 
morphology and are fairly motile, which makes these cells particularly well 
suitable for such study.  
GAR22 genes encodes for two splice variants, GAR22α and GAR22β. Both 
GAR22 variants perfectly co-localized with actin in B16F1 and NIH3T3 cells. 
It was found that the dynamics of GAR22 proteins resembled that of actin 
suggesting that GAR22 is involved in the regulation of actin cytoskeleton 
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remodeling and cell migration. Consistent with this hypothesis I found that 
overexpression of GAR22β greatly impaired directional cell migration.  
To further characterize GAR22 function, I searched for GAR22 interacting 
proteins employing proteomics and mass spectrometry, and identified EB1 
(end binding protein 1). GAR22β interacts with EB1 through its carboxy-
terminal domain. EB1 is a microtubule plus end binding protein that 
regulates stability and dynamics of microtubules. Thus, the GAR22-EB1 
interaction might be involved in the regulation of microtubule dynamics and/ 
or function. This possibility is supported by the observation that 
overexpression of GAR22β displaced EB1 from the plus tips of microtubules, 
causing the collapse of microtubule cytoskeleton. Moreover, overexpression of 
GAR22β also impaired the reassembly of microtubules in nocoazole treated 
cells. Finally, the deletion of either the actin binding domain or the 
microtubule-binding domain within GAR22β reduced the inhibitory 
phenotype of GAR22β on cell migration.  
These findings uncovered a novel function of GAR22β in regulating 
directional cell migration via the control of EB1 localization and microtubule 
dynamics. In this context through its dual binding to microfilaments and 
microtubules GAR22β is proposed to support the functional interplay 
between actin and microtubule cytoskeletons. Thus, this GAR22β activity is 
of fundamental importance for cell motility, and extends beyond its function 
in red cell differentiation.  
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1 Introduction 
1.1 Hematopoietic system 
For mankind blood is seen as the essence of life. It is composed of water, 
minerals, proteins and cells from the hematopoietic system. The main cellular 
components of blood are oxygen-carrying cells: the erythrocytes. 
Hematopoiesis in vertebrate starts already in the yolk sac of the embryo by 
producing early erythrocytes supporting the fast growing embryo, a period 
defined as primitive hematopoiesis. The later stage or definitive hematopoiesis 
begins in the aorta-gonad-mesonephros (AGM) from a new stem cell 
originating from the AGM and possibly also from an earlier progenitor of the 
yolk sac. Later these hematopoietic stem cells (HSCs) move to the fetal liver, 
the spleen and the thymus, and finally after birth to the bone marrow, where 
they differentiate into cells of all lineages of the hematopoietic system 
(Mikkola and Orkin, 2006; Orkin and Zon, 2002; Orkin and Zon, 2008) (Figure 
1.1). However, all mature cells of the hematopoietic system are short-living 
and require a constant replacement throughout the entire life of an individual. 
HSCs localize to specialized niches that provide them with protection and 
crucial signals for survival, proliferation and differentiation. These signals are 
mediated by integrin receptors of HSCs and binding to extracellular matrix 
(Ezoe et al., 2004; Levesque and Simmons, 1999; Zhang et al., 2003a). 
Multipotent HSCs have the capability for self-renewal and the potential to 
differentiate into all cells of the myeloid or lymphoid compartment (Figure 
1.1). 
HSCs and their progeny are characterized by the expression of distinct 
subsets of transcription factors and surface markers that define their cell fate 
and phenotype. Originating from the mesodermal lineage, HSCs have to 
commit themselves to a more restricted developmental program during early 
hematopoiesis. In this context, SCL/tal-1 (T-cell acute lymphocytic leukemia 
1), Bmp4 (bone morphogenetic protein 4) and LMO2 (LIM domain only 2) 
play a fundamental role (Orkin, 1995). In the AGM, MLL (SET-domain 
containing methyltransferase) and Runx1 (runt-domain) are crucial for the 
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development of a hematopoietic stem cell pool (Burns et al., 2005; Wei et al., 
2008). 
HSCs in fetal liver differ from HSCs in the bone marrow in terms of surface 
marker expression, developmental potential and state of cell cycle. During 
definitive hematopoiesis, temporal expression of lineage regulators determines 
the commitment of progenitors. Priming of multipotent HSCs occurs 
dynamically, whereby alternative fates are excluded by a complex regulatory 
network of complementary transcription factors (Cantor and Orkin, 2001; 
Stopka et al., 2005).  
 
 
Figure 1.1: The hierarchy of hematopoietic cells 
Scheme of hierarchy of the hematopietic system shows the differentiation potential of various 
progenitor cells. Reproduced from Larsson and Karlsson, 2005. 
 
1.2 Red blood cell differentiation in vivo 
Red blood cells represent one of the most abundant specialized cell types in 
the human body. In an adult human around 5x1012 red blood cells are present 
in a total average blood volume of 5 liter. Erythrocytes have an average life 
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span of 120 days and therefore have to be constantly generated, 
predominantly from bone marrow, in erythroblastic islands (Chasis and 
Mohandas, 2008). The terminal differentiation to erythrocytes includes 
biosynthesis of hemoglobin, cell membrane remodeling and, in mammals, 
extrusion of the nucleus. 
Erythroid-committed cells undergo various differentiation stages, starting 
with a common myeloid progenitor (CMP), followed by a stage defined as 
burst-forming unit-erythroid (BFU-E). The next stage includes cells of colony-
forming unit-erythroid (CFU-E), which highly proliferate and express 
erythropoietin (Epo) receptor to the highest level detected during lineage 
differentiation. CFU-E cells differentiate into proerythroblasts, which cease 
proliferation and further differentiate. Erythroblasts can be classified into 
basophilic, polychromatophilic and orthrochromatophilic cells, depending on 
the amount of hemoglobin and on the condensation state of the nucleus 
(Denton et al., 1975; Koury et al., 2002). Upon enucleation the cells become 
reticulocytes, which can be already released in the blood stream (Figure 1.2). 
However, reticulocytes undertake a final step with degradation of the 
organelles to reach terminally differentiated erythrocytes (Daniels and Green, 
2000; Koury et al., 2002). The process of erythroid maturation resembles in 
some aspects with apoptosis. Effector caspases are transiently activated 
during the differentiation process to cleave various proteins but without 
inducing apoptosis (Carlile et al., 2004; Zermati et al., 2001). 
 
 
Figure 1.2: Differentiation of erythroid committed cells 
The picture shows examples of erythroid progenitors and their development to erythrocytes, 
starting from the least differentiated on the left to the most differentiated on the right. Modified 
from http://www.med.univ-angers.fr/discipline/lab_hema/page3.html.  
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Regulators of erythropoiesis are mainly transcription factors, which influence 
either the commitment or the differentiation process. A balance between 
commitment, proliferation, and terminal differentiation has to be established, 
for which stem cell factor (SCF) and Epo signaling play a major role (Dolznig 
et al., 2006; Wu et al., 1995). HSCs receive a proliferation stimulus from SCF 
signaling via c-kit, which acts through the Src kinase/c-Myc pathway 
(Munugalavadla et al., 2005). SCF and Epo can work synergistically in 
regulating ERK, thus promoting cell proliferation (Sui et al., 1998). HSCs also 
express GATA-2, LMO2, SCL/tal-1 until the stage of erythroblasts (Koury et 
al., 2002). The zinc-finger protein GATA-2 is a transcription factor that has 
DNA-binding sides in many erythroid genes, like globins, Band 3, EKLF 
(erythroid Krüppel like Factor), and FOG1 (friends of GATA-1) (Perry and 
Soreq, 2002).  
Upon differentiation to the CFU-E state, GATA-1, FOG, and later EKLF 
and NF-E2 (nuclear factor, erythroid-derived 2) play an essential role (Koury 
et al., 2002). GATA-1, like GATA-2, controls many erythroid genes. Its 
expression is regulated by Epo and it can induce cell cycle arrest in G1-phase 
by inhibiting c-Myc and c-kit (Briegel et al., 1996; Cantor and Orkin, 2002; 
Munugalavadla et al., 2005; Rylski et al., 2003; Testa, 2004; Zhao et al., 2006). 
EKLF, another zinc-finger protein mainly regulates the expression of β-globin 
gene (Cantor and Orkin, 2002; Perry and Soreq, 2002). Cells in a BFU-E state 
are Epo dependent. Epo prevents apoptosis, promotes proliferation and 
supports terminal differentiation of erythroid cells by regulating cell cycle 
modulators and anti-apoptotic genes (Dolznig et al., 2002; Fang et al., 2007; 
Richmond et al., 2005; Sivertsen et al., 2006; Testa, 2004). Epo receptor is a 
cytokine receptor signaling via Jak/STAT pathway. Additionally, the 
activation of Jak2 affects phosphatidylinositol-3 kinase (PI3K), AKT kinase 
and Ras signaling pathways (Testa, 2004; Zhang et al., 2003b). At the 
erythroblast stage, cells begin to express erythrocyte-related structural and 
functional proteins, including glycophorins, Band 3, hemoglobin, ALAD 
(delta-aminolevulinic acid dehydratase) and transferrin receptor (CD71) 
(Koury et al., 2002).  
Multipotent HSCs in the bone marrow are in a quiescent state, in G0-phase 
of the cell cycle, though they keep their proliferative potential. Upon 
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stimulation, HSCs can proliferate by asymmetric division, thus giving rise to 
one daughter cell that will differentiate, whereas the other one will remain as 
stem cell in the bone marrow (Ezoe et al., 2004; Steinman, 2002). Already 
committed progenitors have a high proliferation rate, which is in balance with 
the differentiation process. Fully differentiated cells are again quiescent, but 
unable to proliferate. If the balance of proliferation and differentiation is 
shifted to more proliferation, leukemia can occur. If it is shifted to an early or 
faster differentiation anemia could be the outcome. 
Proliferation and maturation is regulated by cell cycle proteins, like cycline 
dependent kinases (cdks) activated by cyclins, and regulatory proteins, such 
as cdk inhibitors, c-Myc and its antagonist Mad1. Following proliferation 
stimuli, progenitor cells are in early G1-phase, where cyclinD/cdk4 or -6 
phosphorylates Rb-E2F1 complex, thereby releasing the transcription factor 
E2F1 (Steinman, 2002; Sun et al., 2007). The progression through G1-phase 
can be repressed by cdk inhibitors like p15, p16 and p18 (INK4 family) or 
p21, p27 and p57 (CIP/KIP family) (Ezoe et al., 2004; Steinman, 2002). Cdk 
inhibitors of the INK4 family are the prominent inhibitors of cdk4, which is 
the main cdk in erythroid progenitors, and cdk6. CIP/KIP family members on 
the other hand target cdk2 in late G1- through early S-phase (Matushansky 
et al., 2000; Steinman, 2002). Throughout erythroid differentiation p15, 
rather than p16 seems to be expressed in early progenitor cells (Della Ragione 
et al., 1997). p21 and p27 have been described as key players for the 
maintenance of the quiescent state of HSCs, by preventing the reentry in the 
cell cycle (Steinman, 2002). In terminally differentiated erythroid cells p27 
triggers cell cycle exit (Hsieh et al., 2000; Tamir et al., 2000). Interestingly, 
factors that regulate the proliferation and differentiation are also dependent 
on the cell cycle progression. For example, GATA-2 oscillates during cell cycle 
progression with high expression in S-phase but low in G1- and G2/M-phase 
(Koga et al., 2007). Cell cycle progression in erythroid progenitors 
concomitantly reduces cell size (Dolznig et al., 1995; Dolznig et al., 2004). With 
shortening of G1-phase, size of cycling erythroid progenitor cells can be 
drastically reduced, due to lack of time for the cells to grow (Dolznig et al., 
1995).  
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One characteristic feature of red blood cells is hemoglobin. It is a complex 
molecule formed of four subunits. Each subunit is composed of a prosthetic 
group, heme, and a globin chain. Heme is a complex of iron (Fe) in a 
porphyrin ring, which main function is to bind oxygen. Heme group 
biosynthesis is a multistep process involving several enzymes and 
compartments in the cell. In erythroid cells, heme group biosynthesis is at a 
maximum, therefore the cells need transferrin (an iron carrier), therefore 
express high levels of transferrin receptor (Ponka, 1999). Different types of 
hemoglobin are known, which are classified by the specific globin protein chain 
attached to the heme group. In the early development, fetal hemoglobin 
(hemoglobin F), a combination of α-globin and γ-globin, is expressed. In 
adults, globin expression switches and hemoglobin A, comprised of α-globin 
and β-globin chains, is predominant (Figure 1.3). The expression of globin 
genes is directly or indirectly controlled by EKLF, GATA-1 and NF-E2 
(Miller, 2002; Peterson, 2003).  
 
 
Figure 1.3: Expression of hemoglobin during embryo development 
Overview of expression pattern of different forms of hemoglobin before and after birth, 
including sites of erythropoiesis at the respective time of development. Reproduced from 
Miller, 2002. 
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1.3 Red blood cell differentiation in vitro 
Red blood cell development can be recapitulated in vitro (Bartunek and 
Zenke, 1998; Dolznig et al., 2001; Panzenbock et al., 1998; von Lindern et al., 
1999; Zhang et al., 2001). In the human system, a source of HSCs is mainly 
umbilical cord blood, and in mice, bone marrow is used to obtain HSCs. 
Recently, a new attempt to generate red blood cells comes from the erythroid 
differentiation of embryonic stem cells (Carotta et al., 2004). Frequently, 
progenitor cells are first amplified with Epo, SCF and glucocorticoids 
(dexamethasone; Dex) (Leberbauer et al., 2005; Panzenbock et al., 1998). Cells 
are then induced to differentiate in the presence of specific differentiation 
factors, such as Epo and insulin yielding fully mature red cells (Figure 1.4). 
Differentiation can be accelerated by using thyroid hormones (Gamper et al., 
2009; Leberbauer et al., 2005).  
The in vitro differentiation process is characterized by morphological changes 
and surface marker expression. Early progenitors are defined by the 
expression of CD34, CD36 and c-kit (Freyssinier et al., 1999). Transferrin 
receptor (CD71) is highly expressed in erythroid progenitors that synthesize 
hemoglobin (Loken et al., 1987). A shift towards the expression of red blood 
cell specific markers, such as Band 3 and glycophorin A/B is particular for the 
in vitro differentiation process (Panzenbock et al., 1998). These in vitro 
differentiation systems have allowed the study of the molecular mechanisms 
that underlie the erythroid differentiation program under well-defined 
conditions (Bartunek and Zenke, 1998; Dolznig et al., 2001; Panzenbock et al., 
1998). 
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Figure 1.4: Schematic representation of SCF/Epo progenitors yielding red blood cells in 
vitro 
Modified from Birgit Panzenböck and Britt Lemke (unpublished) 
 
1.4 The impact of thyroid hormone receptor on erythropoiesis 
Nuclear receptors (NRs) represent a class of transcription factors affecting 
erythropoiesis, including thyroid hormone receptor (TR), retinoic acid 
receptor (RAR), retinoic X receptor (RXR), steroid hormone receptors and 
nuclear orphan receptors (Bartunek and Zenke, 1998; Bauer et al., 1999; 
Carlile et al., 2004; Leberbauer et al., 2005; Wessely et al., 1997). Two TR 
genes exist in mammals, encoding TRα and TRβ, located on different 
chromosomes. TRα and TRβ have been inactivated in mice by gene targeted 
mutations leading to defects, e. g. in growth, bone maturation, heart rate, 
intestine development, body temperature and sensory functions (Flamant and 
Samarut, 2003; Forrest and Vennstrom, 2000; O'Shea and Williams, 2002). 
TRα deficiency leads to defective spleen erythropoiesis in neonatal mice 
(Angelin-Duclos et al., 2005).  
TRs are ligand-dependent transcription factors that regulate gene expression 
by interacting with specific response elements (thyroid hormone response 
elements, TREs) present in thyroid hormone (T3) responsive promoters. TRs 
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can bind to TREs as monomers or homodimers, but they mainly form 
heterodimers with retinoid X receptors (RXR) (Zhang and Lazar, 2000). 
Studies in the past several years have supported the concept that DNA-
bound TR acts as a binary switch to regulate gene expression (Bartunek and 
Zenke, 1998; Bauer et al., 1998; Flamant et al., 2007; Zhang and Lazar, 2000). 
In the absence of the hormone, the TR/RXR heterodimer recruits co-
repressors, such as NcoR1, and SMRT and assembles a large multiprotein 
complex that exhibit histone deacetylase activity by HDAC1 or HDAC3, 
thereby confers transcriptional repression (Harvey and Williams, 2002; Moore 
and Guy, 2005) (Figure 1.5). T3 binding to TR causes dissociation of the co-
repressors and recruitment of co-activators of the SRC family, CBP/p300, 
and p/CAF, which possess histone acetyltransferase activity, thus causing the 
opening of the chromatin that allows greater access to the transcriptional 
machinery (Harvey and Williams, 2002; Moore and Guy, 2005) (Figure 1.5).  
 
 
Figure 1.5: Binary switch of thyroid hormone receptor 
Modified from Petr Bartunek 
 
The model of binary switch is in accordance with previous work, where 
unliganded TR blocks erythroid cell differentiation, whereas ligand-activated 
TR enhances differentiation (Bartunek and Zenke, 1998; Bauer et al., 1998; 
Leberbauer et al., 2005).  
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1.5 Cytoskeletal remodeling in red blood cell differentiation 
A striking feature of erythrocytes is their flexible cell membrane, which confers 
on the red blood cells great stability and deformability during their passage 
through capillaries and splenic endothelial slits (Chasis et al., 1989; Mohandas 
and Groner, 1989). For that, cytoskeletal and membrane remodeling takes 
place during maturation (Chasis et al., 1989). Upon enucleation the 
orthochromatic erythroblast becomes a reticulocyte. This process depends on 
the formation of a contractile actin ring that is assembled in response to Rac 
GTPases and mDia2. Based on this observation, it has been suggested that 
enucleation is a form of cytokinesis (Ji et al., 2008). Immature reticulocytes are 
irregularly shaped and still have cell organelles. During reticulocyte 
maturation the membrane becomes more stable and deformable, which partly 
depends on Rac activation (Chasis et al., 1989; Kalfa et al., 2006). Rac 
GTPases also regulate the actin organization in the erythrocyte cytoskeleton 
and the ratio of actin to other cytoskeletal proteins, like spectrin, adductin 
and dematin (Kalfa et al., 2006). Following the maturation and the loss of 
organelles the shape of reticulocytes changes to a discoid form, an event that 
is accompanied by newly organized cell membrane due to loss of membrane 
phospholipids and various receptors (Chasis et al., 1989; Mohandas and 
Groner, 1989).  
In avian nucleated erythrocytes, microtubules bundle during differentiation 
and finally form a marginal band at the cell membrane without an organizing 
center, which co-aligns with F-actin (Kim et al., 1987; Murphy et al., 1986). 
However, in mammalian enucleating reticulocytes, microtubules form a cage 
around the nucleus and are only found in a diffuse pattern after nucleus 
extrusion in immature reticulocytes (Koury et al., 1989).  
1.6 Actin dynamics and the leading edge 
Actin and microtubule cytoskeletons in other cell types are not only 
important for stability, but also for motility. Cell motility is an essential 
feature of any organism from prokaryotic cells to eukaryotic multicellular 
organism (Li and Gundersen, 2008). It is important for embryogenesis as well 
as for the function of immune cells, the generation of neuronal cell networks 
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and numerous other processes. Cell migration can be schematically divided 
into three steps: protrusion, translocation and detachment of cell membrane 
(Figure 1.6).  
 
 
Figure 1.6: Schematic representation of two-dimensional cell migration 
Reproduced from Lauffenburger and Horwitz, 1996. 
 
To migrate, a cell must acquire a polarized state by establishing a front-rear 
axis (Li and Gundersen, 2008; Ridley et al., 2003). This is defined by 
asymmetric accumulation of proteins and organelles along the axis of polarity 
(Bornens, 2008). A polarized cell has a defined leading and trailing edge. The 
leading edge is a protrusion in form of large and broad lamellipodia or spike-
like filopodia, (Ballestrem et al., 1998; Vicente-Manzanares et al., 2005). Both 
structures are actin-rich and the intrinsic polarization of filamentous actin 
drives the protrusion (Pollard and Borisy, 2003; Welch and Mullins, 2002). 
During a two-dimensional movement the cell stabilizes itself with the 
surrounding extracellular matrix (ECM) via the assembly of focal complexes 
and focal adhesions. The latter also serves as traction sites for cell movement 
(Zaidel-Bar et al., 2004). To complete a movement the cell has to retract its 
rear end (Lauffenburger and Horwitz, 1996). The spatial and temporal 
regulation of these events depends on the activity of the actin and 
microtubule cytoskeleton, as well as on their intimate interplay. These two 
cytoskeletal structures exhibit similar properties. They show structural and 
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kinetic polarity, hydrolyze nucleosides triphosphates and undergo a head-to-
tail polymerization (Cleveland, 1982). 
In migrating cells, zones of actin flow appear in the leading edge starting with 
a lamellipodium, followed by a flat lamella, a transition zone and the cell body. 
The lamellipodium contains the greatest actin density (Small et al., 2002), 
where polymerization is balanced by a myosin-dependent rearward movement 
of the actin meshwork creating a retrograde flow. Actin filaments bundle 
behind the lamellum. Retrograde and anterograde flow of actin meet in the 
transition zone. An anterograde flow of actin can be observed in the cell body 
(Ponti et al., 2004; Salmon et al., 2002; Waterman-Storer and Salmon, 1997). 
The dynamic of actin structures are characterized by a fast growing barbed 
end (plus end) and a slow growing pointed end (minus end). The structural 
orientation is reached by the hydrolysis of ATP-actin, which leads to 
polymerization of filamentous actin (F-actin). The regulation of actin 
polymerization is summarized in Figure 1.7.  
The polymerization of actin is regulated by numerous proteins involved in the 
assembly/disassembly and the stabilization of actin filaments (Chhabra and 
Higgs, 2007; Pollard, 2007; Svitkina and Borisy, 1999). There are two classes 
of actin nucleators: Arp2/3 complex (actin related protein), which is able to 
nucleate actin resulting in a branched actin meshwork (lamellipodium), and 
formins (mDia), which can form linear arrays of actin filaments (filopodium). 
The Arp2/3 complex promotes actin polymerization and thereby contributes 
to lamellipodia protrusion (Machesky et al., 1997; Welch et al., 1997). It is 
regulated by nucleation-promoting factors, which are members of the 
WASP/WAVE family (Bear et al., 1998; Disanza and Scita, 2008; Machesky 
and Insall, 1998; Yarar et al., 1999). The conserved carboxy-terminus of 
WASP is a catalytic core that can bind G-actin (monomers) and the Arp2/3 
complex (Machesky and Insall, 1998; Suetsugu et al., 1999). WASP and N-
WASP can be activated by cdc42 and are essential for the formation of special 
adhesive structures, like podosomes and invadopodia (Ridley et al., 2003; 
Rohatgi et al., 1999). WAVE does not have a GTPase binding domain, but it 
forms a complex, which is regulated by Rac1 (Le Clainche and Carlier, 2008; 
Miki et al., 1998). N-WASP can be found along actin filament bundles of 
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microspikes, whereas WAVE is rather distributed along the lamellipodium 
edge (Nakagawa et al., 2001).  
Formins, a second class of nucleators, polymerize actin in a linear way. They 
remain associated with actin filaments during elongation, thereby 
antagonizing capping proteins (Faix and Grosse, 2006; Le Clainche and 
Carlier, 2008). Formins are involved in a wide range of actin-based processes, 
like formation of actin cables, stress fibers, contractile ring formation and 
filopodia protrusion, as well as focal adhesion formation (Higashida et al., 
2008). Formins are regulated by small GTPases, which release the auto-
inhibitory conformation of formins (Le Clainche and Carlier, 2008). mDia1, a 
member of the formin family, is found at the tip of filopodia, where it localizes 
with profilin. mDia is also an effector of RhoA. Important for the formation 
of filopodia structures is also Ena/VASP, which causes the dissociation of 
capping proteins from barbed ends, and Mena, which can bundle linear 
filamentous actin (Bear et al., 2002; Svitkina et al., 2003). 
Profilin binds monomeric ADP-actin and catalyses nucleotide exchange to 
ATP-actin, thereby controlling the turnover of microfilaments (Carlsson et 
al., 1977; Romero et al., 2007; Selden et al., 1999). Profilin localizes exclusively 
to the barbed end of filamentous actin. Ena/VASP proteins, which recruit 
profilin to the site of nucleation, increase actin polymerization (Krause et al., 
2004; Laurent et al., 1999; Pollard and Borisy, 2003; Reinhard et al., 1992; 
Welch and Mullins, 2002). Actin dynamic is also regulated by 
depolymerization factors, like ADF and cofilin (Lee and Keng, 2005). ADF can 
bind ADP-actin and prevent nucleotide exchange. If ADF becomes 
phosphorylated by LIM kinase, it will release ADP-actin. Thus, ATP-actin 
can be formed and actin filaments can reassemble (Gungabissoon and 
Bamburg, 2003).  
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Figure 1.7: Regulation of actin polymerization 
Reproduced from Cell signaling, Danvers, MA, USA. 
 
1.7 Environmental contact via focal adhesions 
The contact with the substratum, which is newly formed as the cell moves, 
allows the cell to communicate with its surrounding. These contact sites are 
named focal adhesions and assemble around integrin receptors. Migration 
speed of a cell in a two-dimensional system depends on the strength of 
attachment to the substratum (detachment vs. adhesion) that can be 
determined by the density of ligands, as well as availability and affinity of 
receptors (Beningo et al., 2001; Galbraith et al., 2002).  
The integrin-mediated adhesion provides a point for the cell to build 
contractile or tensile force. Integrins are heterodimer transmembrane receptors 
consisting of one α- and one β-subunit (Zamir and Geiger, 2001). The 
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combination of different α- and β-subunits creates a variety of receptors 
specific for binding to different components of the ECM (extracellular 
matrix). Also, the affinity to the substrate is ‘tunable’ by signaling cascades 
resulting in conformation change of the integrins (Carman and Springer, 
2003; Hynes, 2002). The intracellular domain of integrins is linked to actin 
filaments by talin, α-actinin, and vinculin. Vinculin also binds to actin, talin 
and α-actinin (Critchley, 2000; Weiss et al., 1998). Any disruption of the 
interaction of those proteins weakens the integrity and stability of an 
adhesion side leading to the disassembly of the focal adhesions (Critchley, 
2004; Gilmore and Burridge, 1996; Hemmings et al., 1996; Otey et al., 1990). 
At the new assembling adhesion side, small dot-like nascent focal contacts are 
formed that are cdc42- and Rac-dependent (DeMali et al., 2002). Different 
components of the focal adhesions are recruited in a hierarchical order. It 
starts with integrins, talin and paxillin, followed by vinculin and α-actinin 
with focal adhesion kinase (FAK) and Ena/VASP protein cluster (Ballestrem 
et al., 2001; Rottner et al., 1999; Webb et al., 2002; Zaidel-Bar et al., 2003). 
With the movement of the cell and the lamellipodia pushing forward, the 
newly formed focal contacts move to the back. At the end of the lamellipodia, 
where the actin organization changes from a dendritic meshwork to linear 
bundles, the focal contact can be either turned over or mature. At this point, 
FAK is a trigger for adhesion turnover by downregulating myosin-generated 
force (Schober et al., 2007). The maturation of focal adhesions depends on 
assembly of actin bundles mediated by RhoA and mDia, which then can 
apply force via actomyosin contractility (Webb et al., 2002). The mature focal 
adhesions become a robust and dynamic structure with a polar extension in 
the direction of stress fibers, where actin stability via crosslinking and 
bundling is a defining factor (Zaidel-Bar et al., 2004).  
Microtubules are also linked to focal adhesions. Contact sites stabilize 
microtubules against depolymerization and promote microtubule assembly 
(Kaverina et al., 1998). The contact of microtubules with the adhesion site 
can lead to the instability of the focal adhesion by local release of tension 
resulting in disassembly of focal adhesions (Kaverina et al., 1999; Kaverina et 
al., 1998).  
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1.8 Polarity and microtubule structure 
Establishing polarity is crucial for migration. Therefore, plus ends of 
filamentous actin are subadjacent to the cell membrane and the minus end 
pointing toward the cell interior (Small et al., 2002). Additionally, microtubule 
plus ends reach to the cell periphery. The minus ends, however, are connected 
with the centrosomes between the nucleus and the leading edge. Cell 
polarization is a temporal and spatial event, which provides an asymmetry 
within the cell. The process also involves the reorientation of the Golgi, the 
nucleus and the microtubule-organizing center (MTOC) (Gomes et al., 2005). 
The polarity-protein-complex containing Par6, Par3 and atypical protein 
kinase C (aPKC) is a highly conserved structure. Par6 and aPKC are direct 
targets of cdc42 and therefore crucial for microtubule polarization and cell 
orientation, since Par6 and aPKC regulate the dynein/dynactin complex and 
adenomatous polyposis coli (APC) (Etienne-Manneville et al., 2005; Joberty et 
al., 2000; Lin et al., 2000).  
Many other functions in the cell also depend on microtubule dynamics, like 
the formation of mitotic spindle and the capture of kinetochores for an 
organized cell division. Microtubules function as tracks for transport of 
organelles or vesicles by motor proteins (dynein/dynactin), thereby influencing 
the polarity of the cell. Microtubules nucleate from the centrosomes or other 
MTOCs. Microtubule arrays can be aster-shaped or orientated in a 
parallel/anti-parallel way (Bartolini and Gundersen, 2006). With establishing 
a minus and a plus end in the aster arrays, microtubules become a polar 
structure. The minus end terminates with α-tubulin, whereas the plus end 
terminates with β-tubulin (Bartolini and Gundersen, 2006). The microtubule 
tube grows with the polymerization and hydrolysis of GTP-tubulin. 
Microtubules are always in a state of dynamic instability leading to a 
stochastic switch between growth and shrinkage (Akhmanova and Steinmetz, 
2008). The transition from growth to shrinkage is called catastrophe, and the 
opposite event rescue. A third state in between is called pause. Those events 
are regulated by a variety of microtubule-associated proteins (MAPs). A sub-
group of MAPs called +TIPs (plus end tracking proteins) are a group of 
structurally unrelated proteins found at the tip of newly polymerized 
microtubules. They regulate the stability and capture of the microtubule to 
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the cortical cortex thereby generating pulling forces (Komarova et al., 2009). 
The capture can result in a diversity of stable microtubules, ranging from 
transient increase in pause to long-term capping.  
The gathering of +TIPs at the plus end is probably mediated by structural 
differences between the microtubule tip and the microtubule lattice 
(Akhmanova and Steinmetz, 2008; Carvalho et al., 2003). It is thought, that 
+TIPs recognize sheets of individual protofilaments before they become 
organized in a tube. With a lower affinity to the lattice than to the end, 
+TIPs reveal a comet-like tail shape on the microtubules (Morrison, 2007). 
Also, +TIPs often become located at the plus end by hitchhiking, where they 
use another +TIP for transportation (Lansbergen and Akhmanova, 2006). 
Many +TIPs are able to bind microtubules directly, among them are CLIPs, 
EBs, dynein/dynactin motor complex, CLASPs, ACF7 (MACF), APC, LIS1, 
MCAK (kinesin 1 kinase), and melanophilin, a myosin V associated protein. 
But they can also interact with each other, which promote additional binding 
(Berrueta et al., 1999; Bieling et al., 2008; Bu and Su, 2001; Hayashi et al., 
2005; Mimori-Kiyosue et al., 2005). The +TIPs are able to generate force on 
microtubules directly by interacting with motor proteins (dynein) or 
indirectly by binding to actin-based motor proteins (myosin V via 
melanophilin) (Carvalho et al., 2003). The regulation of microtubules is 
summarized in Figure 1.8.   
The activation of plus-end binding proteins can be regulated by 
phosphorylation, auto-inhibition or by post-translational modifications of 
microtubules. Phosphorylation of binding proteins can affect their affinity to 
microtubules. For example, APC and CLASPs can be phosphorylated by 
GSK3β, which can alter the binding of the proteins to microtubules 
(Wittmann and Waterman-Storer, 2005). The same was seen for APC and 
EB1 and their phosphorylation by cdc2 (cell division cycle 2) (Askham et al., 
2000). Auto-inhibition is a regulatory conformation of EB1 and CLIPs 
(Hayashi et al., 2007).  
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Figure 1.8: Regulation of microtubule dynamics 
Reproduced from Cell signaling, Danvers, MA, USA. 
 
Microtubules are also structures that become reversibly post-translationally 
modified. The modification can influence the properties of microtubule, 
making them accessible for +TIPs or severing proteins (van Dijk et al., 2007). 
The carboxy-terminus of tubulin, which is located on the outside of the tube 
polymer, is almost always modified. Several types of modifications are known. 
One is the tyrosination/detyrosination, where tyrosine residues are removed 
from and subsequently re-added to the carboxy-terminus of α-tubulin. 
Microtubules, which have a higher content of detyrosinated tubulin, are long-
lived structures, whereas highly dynamic microtubules contain tyrosinated 
tubulin (Gundersen and Bulinski, 1988; Gundersen et al., 1987; Infante et al., 
2000). Other types of modifications are polyglycylation and polyglutamylation, 
where either polyglycine chains or polyglutamate chains, respectively, are 
attached to glutamate residues in the carboxy-terminus (CTT region) of α- 
or β-tubulin subunits (van Dijk et al., 2007). Polyglycylation is restricted to 
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axonemes, like cilia or flagella, whereas polyglutamylation can be found in 
neuronal cells, centrioles, axonemes and mitotic spindles (Westermann and 
Weber, 2003). Another important modification, which is not restricted to the 
carboxy-terminus, is acetylation. Lysine 40 of the α-tubulin subunit is 
acetylated by a, so far unknown, enzyme. The deacetylation occurs via 
HDAC6 (histone deacetylase 6) and Sirt2 (sirtuin 2) (Pandithage et al., 2008; 
Valenzuela-Fernandez et al., 2008). This modification can be found in stable 
microtubules, where it may play a role in motor-based transport (Bulinski, 
2007; Reed et al., 2006).  
A main regulator of microtubule turnover is the oncoprotein 18/stathmin 
protein family. It contributes to the rapid reorganization of the microtubule 
cytoskeleton, and is highly expressed in leukemia and high proliferating breast 
cancer cells. Stathmin expression can be found in cells with proliferating 
potential, whereas its levels are lower in terminal differentiated cells. Stathmin 
reduces the level of tubulin available for assembly and/or stimulates plus end 
catastrophes. The function of stathmin is tightly regulated by 
phosphorylation, which inactivates its destabilizing activity. For that, 
stathmin is hyperphosphorylated during G2/M transition of the cell cycle and 
during mitosis (Cassimeris, 2002).  
1.9 Actin-Microtubule interaction 
Since long it has been appreciated that cell motility depends on the dynamic 
interaction between actin and microtubule cytoskeletons. For instance, it has 
been observed that microtubules are coupled to the retrograde and 
anterograde flow of actin (Rodriguez et al., 2003). Microtubules can move 
perpendicular or parallel to the lamellum. While the perpendicular movement 
can only be observed in the cell body and in the lamellum (Salmon et al., 
2002; Vallotton et al., 2004), the parallel movement seems to be associated 
with the flow of actin possibly in a passive way (Gupton et al., 2002; Salmon 
et al., 2002). The transport of microtubules rearward in the lamella depends 
on actomyosin contractility. The interaction of microfilaments and 
microtubules can be regulatory or structural (Rodriguez et al., 2003).  
A regulatory interaction can be accomplished when microfilaments and 
microtubules indirectly control each other. For example, RhoGTPases 
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influence both structures. Another is WHAMM, a member of the 
WASP/WAVE family, which is found near the MTOC and the Golgi. It has a 
putative profilin binding domain and a coiled-coiled region, which can interact 
with microtubules (Disanza and Scita, 2008). Moreover, formins the family of 
actin nucleator have an influence on microtubule cytoskeleton, since mDia 
seems to be sufficient and necessary to orientate and stabilize microtubules 
via APC, EB1 and ACF7 (Bartolini et al., 2008; Ezratty et al., 2005; Palazzo 
et al., 2001). Consequently, this has an influence on mitotic spindle 
positioning and microtubule attachment to the kinetochores. The cross talk of 
the two structures is needed in the cells to establish and maintain polarity 
(Kodama et al., 2004). For example, microtubules serve as tracks to 
concentrate regulatory molecules for actin cytoskeleton at a particular place at 
the cell cortex. APC is one protein, which directs the plus ends of 
microtubules to the cell cortex, where it can interact with actin-binding 
proteins, like mDia or IQGAP (a RhoA effector) to anchor the microtubules 
(Fukata et al., 2002; Tirnauer, 2004). In addition, microtubules act on focal 
adhesions, which in turns are linked to stress fibers (Kaverina et al., 1999). 
Actin, on the other hand, contributes to microtubule assembly by positioning 
the centrosomes.   
The structural regulation can be found in proteins, which can physically link 
microfilaments and microtubules. An important component are 
spectraplakins, which contain features of both spectrin and plakin family 
(Roper et al., 2002). Spectrin superfamily members bind and crosslink actin 
filaments and attach them to membrane receptors. Characteristics of spectrin 
superfamily are a amino-terminal actin-binding domain with two CH domains 
and α-helical spectrin repeats (Leung et al., 1999). Members of the plakin 
superfamily connect adhesion receptors to intermediate filaments, and 
crosslink different cytoskeletal elements. Their characteristics are a plakin 
domain at the amino-terminus and a set of short repeats named plectin 
repeats, which bind to intermediate filaments (Ruhrberg and Watt, 1997). 
The plakin domain has microtubule-binding activity and since spectraplakins 
also contain a second microtubule-binding domain (GAR/Gas2 domain), they 
can interact with all three cytoskeletal elements (Leung et al., 2002). Taken 
together, spectraplakins function as crosslinkers of cytoskeletal filaments and 
link the cytoskeletons to the plasma membrane. They can also act as scaffold 
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proteins, which recruit signaling proteins to the site of cytoskeletal activity. 
Members of the spectraplakin family are MACF, BPAG1 in mammalian, and 
kakapo/shortstop in Drosophila (Roper et al., 2002). 
MACF is highly expressed in the nervous system and to a lower extent in 
skeletal muscles. MACF contains an actin-binding domain (2 CH domains), a 
plakin domain, a rod domain with 23 spectrin repeats, and a microtubule-
binding domain (Byers et al., 1995; Jefferson et al., 2004; Leung et al., 2002). 
It was proposed that it acts as a cytoskeletal linker since it can interact with 
F-actin and microtubules. (Sun et al., 2001). Upon stimulation of intercellular 
adhesion formation, MACF reorganizes with microtubules and relocates to 
sites of cell-cell contact. MACF homologue in Drosophila, kakapo/shortstop 
(Lee et al., 2000) localizes to the termini of microtubule bundles in muscle-
dependent tendon cells (epidermal muscle cells). Absence of kakapo causes the 
detachment of microtubule bundles from the basal membrane (Subramanian 
et al., 2003). Kakapo/shortstop is important for axonal outgrowth and 
guidance, and dendrite development in neurons. In kakapo/shortstop 
mutants, the intersegmental nerve motor axon fails to develop leading to 
extensive loss of axons in sensory neurons (Lee et al., 2000). 
Kakapo/shortstop recruits EB1/APC in tendon cells and forms a complex 
with EB1 via its carboxy-terminal EF hand and Gas2/GAR domains (Leung 
et al., 2002; Subramanian et al., 2003). The interaction of the two components 
of the cytoskeleton allows the cell, and as a consequence the tissue, to keep its 
architecture and resist to mechanical stress.  
1.10 Gas2 related gene on chromosome 22 (GAR22) 
GAR22 was first identified in a screen of various tumor types, which showed 
deletions of a part of chromosome 22. Genomic analysis revealed that GAR22 
was one of the genes encoded in this particular region (Zucman-Rossi et al., 
1996). Therefore, GAR22 was considered as a potential candidate for tumor 
suppressor activity. GAR22 is diminished in all acute myeloblastic leukemia 
(AML) karyotypes, which were analyzed (Desmond et al., 2007). GAR22 is 
expressed in almost all tissues with exception of skeletal muscle cells. 
Particular high expression can be seen in heart, brain and pancreas 
(Goriounov et al., 2003; Zucman-Rossi et al., 1996). Two splice variants are 
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known; depending on the presence or absence of exon 5B, a smaller or larger 
protein can be translated (Figure 1.9). The GAR22 protein shares homologies 
with Gas2 (growth arrest specific gene 2) (Zucman-Rossi et al., 1996). 
GAR22 contains a CH domain, which binds to actin filaments and a GAR 
domain, also described in Gas2, which binds to microtubules (Goriounov et 
al., 2003). GAR22 is upregulated in somatic cells in comparison to embryonic 
stem cells (Player et al., 2006). The promoter of GAR22 contains CpG islands 
and GAR22 is a target of nanog, E2F and ligand-bound TR (Boyer et al., 
2005; Gamper et al., 2009; Weinmann et al., 2002).  
 
 
Figure 1.9: Schematic representation of GAR22 splice variants 
Upper panel for each variant is genomic distribution (blue, exons; red, mRNA), lower panel is 
protein sequence with known domains (CH: calponin homologue domain; GAR: GAR 
domain). 
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1.11 Objective 
Thyroid hormone T3 accelerates terminal differentiation of red cells in vivo 
and in vitro and initial studies identified thyroid hormone receptor (TR) 
target genes. However these genes can only partially explain the T3 induced 
phenotype.  
The first object was therefore to identify further TR target genes by 
employing an in vitro culture system of erythroid progenitors (referred to as 
SCF/Epo cells) to investigate the differentiation process of erythroid 
progenitor cells in response to T3 and a systematic unbiased genome-wide 
approach using DNA microarrays. The second objective was to determine the 
impact of a selected TR target gene – in this instance of GAR22 – on red cell 
differentiation and cell cycle control. To investigate the molecular mechanism 
of GAR22 activity in depth, a third objective was to identify GAR22 binding 
partner by employing proteomics and mass spectrometry. Fourth, my studies 
aimed at mapping the binding sites and to analyze the impact of this 
interaction in vitro and in vivo, with a focus on cytoskeletal dynamics.  
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2 Material and Methods 
2.1 Material 
If not indicated otherwise, all chemicals were purchased from Sigma (St Louis, 
MO, USA) or Merck (Schwalbach/Ts., Germany) in analytical grade. 
Restriction enzymes, Klenow fragment and DNA-polymerase were purchased 
from Fermentas (St. Leon-Rot, Germany). DNA and protein ladder were 
purchased from Fermentas and prepared according to manufacture’s 
instruction.  
2.2 Vectors and bacteria strains 
2.2.1 Vectors 
All backbone vector maps are in 6.3. pflagGAR22 vector containing human 
GAR22β cDNA sequence (kind gift of R.K. Liem, Columbia University, New 
York, USA) was used as template for cloning GAR22 variants. Fragments 
generated by polymerase chain reaction (PCR) were first cloned into pcDNA-
TOPO vector by TA cloning (Invitrogen, Carlsbad, CA, USA). If required 
fragments were also cloned into pBlueskript-KS+ (Stratagene, La Jolla, CA, 
USA) to acquire additional restriction sites for further cloning.  
Various GAR22-GFP fusion genes (GAR22α, GAR22β, GAR22C) were 
generated in pEGFP-N1 (Clontech, BD Biosciences, San Jose, CA, USA). 
Therefore, specific primer sets were designed (see Table 2.3), which contain 
EcoRI and BamHI sites in the forward primer and a SalI site in the reverse 
primer. The stop codon of GAR22 was removed, because GFP sequence is 
located carboxy-terminal of GAR22 coding sequence. Deletion mutants 
GAR22ΔCH, and GAR22ΔGAR were generated based on pEGFP-N1-GAR22β 
using specific primer (Table 2.4).  
Additionally, GAR22β and GAR22C were generated with stop codon from 
pflagGAR22 vector using similar primer design as described above (Table 2.3), 
to clone into pEGFP-C1 (Clontech, BD Biosciences, San Jose, CA, USA). In 
this vector the GFP is located amino-terminal of GAR22 coding sequence.   
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GAR22α, GAR22β, GAR22C were cloned into the inducible vector pRevTre 
(Clontech, BD Biosciences, San Jose, CA, USA) from pEGFP-N1 by BamHI 
and SalI. Then, GFP was taken from the respective pBlueskript vectors 
containing the GAR22-GFP sequence by BstXI and HindIII (for GAR22β, 
GAR22C) and HindIII and SalI (for GAR22α) and cloned carboxy-terminal of 
GAR22 in pRevTre to gain again GAR22-GFP fusion genes. To generate the 
control vector pRevTre-GFP, the GFP was taken from pBlueskript-GAR22α-
GFP by SalI and HindIII.  
GAR22α, GAR22β, GAR22C, GAR22ΔCH and GAR22ΔGAR were cloned 
into retrovirus-vector pMSCV-GFP (generated from pMSCV-puro by 
Antonio Sechi, Institute for Biomedical Engineering, RWTH Aachen 
University, Aachen, Germany) by BglII and SalI from respective pEGFP-N1 
vectors.  
To clone GAR22β, GAR22C into pcDNA5/FRT/TO/NTAP (kind gift from 
Bernhard Lüscher, Institute for Biochemistry, RWTH Aachen University, 
Aachen, Germany), pcDNA-TOPO with the respective GAR22 sequences 
(containing a stop codon) were digested with BamHI, blunt ended by Klenow 
fragment and followed by NotI digest. 
The deletion mutants (GAR22Δ371 GAR22Δ399, GAR22Δ417, GAR22Δ503, 
GAR22Δ589) were generated by PCR (for primer sequence see Table 2.3), 
following EcoRI and SalI digest. GAR22α, GAR22β, GAR22C, GAR22Δ371 
GAR22Δ399, GAR22Δ417, GAR22Δ503, GAR22Δ589 were cloned into 
pGex4T1 (Amersham, GE Healthcare, Piscataway, NJ, USA). pcDNA-TOPO 
vectors were used with respective GAR22 sequences containing a stop codon. 
Briefly, pcDNA-GAR22αstop was digested with BamHI and SalI; pcDNA-
GAR22βstop was digested with EcoRI, blunt ended by Klenow and followed 
by SalI digest. The pcDNAGAR22Cstop vector was digested with EcoRI, 
blunt ended by Klenow and followed by NotI digest, here the pGex4T1 vector 
was digested with SalI, blunt ended with Klenow and followed by NotI digest.  
GAR22 sequences containing point mutations of potential phosphorylation 
sites were generated by site-directed mutagenesis (see 2.3.2) using pGex4T1-
GAR22β as template. GAR22-T334AS394A and GAR22-allT/S-A were taken 
from pGex4T1 and cloned into pEGFP-C1 with BamHI digest, blunt ended 
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with Klenow following SalI digest. The vector pEGFP-C1 was digested as 
followed: XhoI, blunt ended by Klenow and followed by SalI digest.  
Cloning was done by ligation using 10 U T4 ligase (Fermentas, St. Leon-Rot, 
Germany). All vectors were fully or partially sequenced (MWG, Ebersberg, 
Germany) to insure sequence integrity after PCR and cloning. 
2.2.2 Bacteria strains 
Transformation of bacteria was done as follows: purified plasmid DNA or 
ligation mix were added to bacteria suspension and incubated on ice for 30 
min, 1 ml of LB medium (10 g tryptone, 5 g yeast extract, 10 g sodium 
chloride in 1 l H2O, pH 7.0) were added, incubated for 1 hour at 37°C in a 
shaker. Bacteria suspension was plated on LB-agar plates containing 
respective antibiotic (100 µg/ml ampicillin or 30 µg/ml kanamycin) and 
cultured over night at 37°C. The next day, colonies were picked and liquid 
cultures were inoculated. Plasmid DNA was prepared by mini- or maxi-
preparations using kits provided by Qiagen (Hilden, Germany) or Machery & 
Nagel (Düren, Germany) following the manufacturer’s instructions.   
 
Table 2.1: Bacteria strains and respective information 
Bacteria strain Genotype Usage  
DH5α F- φ80lacZΔM15 Δ(lacZYA-argF) U169 
recA1 endA1 hsdR17 (r
k
-, m
k
+) phoA 
supE44 λ- thi-1 gyrA96 relA1 
amplification of plasmids 
(2.2.2) 
XL10 TetrD(mcrA)183 D(mcrCB-hsdSMR-
mrr)173 endA1 supE44 thi-1 recA1 gyrA96 
relA1 lac I [F´ proAB lacIqZDM15 Tn10 
(Tetr) Amy Camr] 
site-directed mutagenesis 
(2.3.2) 
BL21(DH3) B F– ompT hsdS(rB– mB–) dcm+ Tetr gal l 
(DE3) endA I [argU ileY leuW Camr] 
protein purification (2.18) 
  
2.3 Polymerase chain reaction (PCR) 
2.3.1 Reverse transcriptase PCR 
Total RNA was prepared with RNAeasy Kit and DNAse treatment (Qiagen). 
RNA was measured and concentration determined. 1 µg RNA was reverse 
transcribed using High-capacity cDNA Reverse Transcription Kit (Applied 
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Biosystems, Foster City, CA, USA) and 50-100 ng cDNA were used for PCR. 
cDNA was subjected to quantitative real time PCR (RT-PCR) with primers 
and conditions summarized in Table 2.2. Quantitative RT-PCR was done by 
TaqMan PCR (Applied Biosystems) according to the manufacture’s protocol 
using SYBR Green PCR Master Mix (Applied Biosystems). The relative 
expression level of target genes was calculated as followed: ΔCt = Ct (sample) 
– Ct (calibrator, actin); ΔΔCt = ΔCt (treatment, time point) - ΔCt (baseline); 
ratio of expression was calculated by 2-ΔΔCt (Livak and Schmittgen, 2001). 
 
Table 2.2: Primer pairs used for RT-PCR  
Gene Primer pairs (5’ → 3’) 
Annealing 
temper-
ature 
Cycle 
numbers 
PCR 
product 
(bp) 
Actin 
sense: CAAACATGATCTGGGTCATCTTCT 
anti-sense: GCTCGTCGTCGACAACGGCTC 57°C  28 450 
ALAD 
sense: ATTTCTTTCCTGCTTCCCAACC 
anti-sense: CTTCCTCAACAGATGGATTGCC 56°C 28 313 
BTEB1 
sense: AATCCTCCCATCTCAAAGCCC 
anti-sense: AGCACCTCACAAAGCGTTGG 60°C 30 275 
c-kit 
sense: CCATCCATCCATCCAGGAAAATC 
anti-sense: CCTTGGGGTCAGGAATAAACCTC 56°C 26 394 
EKLF 
sense: CCCCTCCTTCCTGAGTTGTTTG 
anti-sense: TTCTTGTCCCATCCCCAGTCAC 62°C 26 444 
EpoR 
sense: GGTGCTGGACAAATGGTTGC 
anti-sense: AAGGCTGTTCTCATAAGGGTTGG 59°C 26 373 
GAR22 
sense: AGTTTGAGCAGGAGATTGAGCG 
anti-sense: CGACACCCTCTGTGGAGAAAAG 57°C 30 416 
GATA-1 
sense: CCCTGTCCCCAATAGTGCTTATG 
anti-sense: CGAGTCTGAATACCATCCTTCCG 60°C 26 447 
GATA-2 
sense: CGGAAGATGTCCAACAAGTCCAAG 
anti-sense: ATGCTGGGCTGGTAAGGGTTTG 61.5°C 30 320 
LMO2 
sense: CCTTCAGAGGAACCAGTGGATGAG 
anti-sense: ACCGTCTTGCCCAAAAAGCC 60°C 26 243 
p21/cip 
sense: TCCAAGAGGAAGCCCTAATCCG 
anti-sense: TTTGATGATGCCCCCACTCG 58°C 30 525 
 
p27/kip1 
sense: TCAGACGGTTCCCCAAATGC 
anti-sense: CATCCAACGCTTTTAGAGGCAG 
 
53°C 
 
26 
 
278 
p57/kip2 
sense: TCCTCTCCTTTCCCCTTCTTCTC 
anti-sense: TCGTAATCCCAGCGGTTCTG 57°C 32 260 
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2.3.2 PCR for cloning 
For generation of GAR22 versions (2.2.1), primers were designed with 
overhang sequences containing restriction enzyme sites, stop or start codons, 
when applicable, and Kozak sequence (Kozak, 1987) for enhanced translation. 
In these PCRs annealing temperature of 55°C was applied. Primers used are 
listed in Table 2.3.  
 
Table 2.3: Primers used for cloning into pEGFP-N1 and pGex-4T1 
 
Numbers in gene name indicate base pairs in human GAR22 cDNA sequence, green: 
introduced restriction enzyme site; blue: start codon; red: stop codon; purple: removed stop 
codon   
 
Deletion mutants GAR22ΔCH and GAR22ΔGAR were generated using 
overlap-extension PCR. Briefly, specific primers were designed (Table 2.4) 
bordering the sequence desired to be deleted. In a first step, two separate 
PCRs were performed generating fragments upstream and downstream of 
deletion site. These two PCR products contain sequences, which allow them 
to align in a following PCR. The complete fragment is then amplified with 
primers inside of the before generated products (nested PCR). The principle 
is pictured in Figure 2.1. 
Vector Gene name Primer (5’ → 3’) 
GAR22-1-EcoRI/BamHI 
(GAR22α/ GAR22β) 
GGAATTCGGGATCCGACCATGGCAGACCCAGTGG
CG 
GAR22-2046-SalI (GAR22β) CGTCGACGGTAACATCCAGGAATCTGGCTCAGC 
GAR22-958-EcoRI/BamHI 
(GAR22C) 
GGAATTCCGGATCCGACCATGACTCCCGTTAGCT
TA 
GAR22-1014-SalI (GAR22α) GGTCGACCGATTTTCATCGGGCCTGGGTGGGGTC
TC 
GAR22-2046-stop (GAR22β) CGTCGACGGTCACATCCAGGAATCTGGCTC 
pE
G
FP
-N
1 
GAR22-1014-stop (GAR22α) GGTCGACCGTCACCTGGGTGGGGTCTC 
GAR22_1 for CCGGAATTCACTCCGACCATGGCAGACCCAGTGG
CG 
GAR22_1251 rev CGTCGACCTAGCTTCGGGGCCCAGGCAG 
GAR22_1509 rev CGTCGACCTAGAGCTGCAGGGGTGTGCG 
GAR22_1767 rev CGTCGACCTAGGCTCCCCTGCCTCCTGG 
GAR22_1113 rev CGTCGACCTAACTGCGGGTACCAAGGGG p
G
EX
-4
T1
 
GAR22_1197 rev CGTCGACCTACCGTCTCGGAGAGGCCGG 
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Figure 2.1: Principle of overlap-extension PCR 
Reproduced from (Heckman and Pease, 2007) 
 
Table 2.4: Primers used for overlap-extension PCR 
 Gene name Primer (5’ → 3’) 
1. PCR (ΔCH/ ΔGAR ) GAR22_520_for GACGCAAATGGGCGGTAGGC 
1. PCR (ΔCH) GAR22_CH_rev 
GCAGGCCCAGGCGTGCCACGTAGGCCTCACT
GG 
1. PCR (ΔGAR) GAR22_GAR_rev 
GTGGGCGATGAGCAGTCAGGTCGCTGGGTGT
CAT 
1. PCR (ΔCH) GAR22_CH_for 
CCAGTGAGGCCTACGTGGCACGCCTGGGCCT
GC 
1. PCR (ΔGAR ) GAR22_GAR_for 
ATGACACCCAGCGACCTGACTGCTCATCGCC
CAC 
1. PCR (ΔCH/ ΔGAR ) GAR22_2890_rev CTTGCCGGTGGTGCAGATGAA 
2. PCR GAR22_580_nfor GTCAGATCCGCTAGCGCTAC 
2. PCR GAR22_2830_nrev CCTCGCCGGACACGCTGAAC 
 
Numbers in gene name indicate base pairs (bp) in pEGFP-N1-GAR22β. CH: calponin 
homologue domain from bp 81 to 441; GAR: GAR domain from bp 618 to 834 in human 
GAR22β.  
 
To introduce point mutations, site-directed mutagenesis was performed 
according to Stratagene protocol. Briefly, pGex-GAR22β was used as 
template. Primer sets with specific point mutations for Serine or Threonine 
residues to Alanine transition were designed (Table 2.5) by online software 
(Stratagene) and used for PCR with Phusion DNA polymerase (Finnzymes, 
Espoo, Finland). Annealing temperature of 55°C for 1 min and 5.5 min for 
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elongation at 72°C were applied. Cycles were repeated 18 times. Restriction 
enzyme DpnI (Fermentas) was used to digest parental methylated and hemi-
methylated DNA. XL10 bacteria were used for transformation and 
amplification of mutated plasmids (2.2.2). 
 
Table 2.5: Primer pairs used for site-directed mutagenesis 
Gene name Primer pairs (5’ → 3’) 
GAR22-T193A  
sense: CCGCACCAGGGGCTCCTGCCCGC 
anti-sense: GCGGGCAGGAGCCCCTGGTGCGG 
GAR22-S292A 
sense: GAGGGTCTGCACCTTTGCTCCACAGAGGG 
anti-sense: CCCTCTGTGGAGCAAAGGTGCAGACCCTC 
GAR22-T334A 
sense: AGGGGCCCGAGGCCCCACCCAGG 
anti-sense: CCTGGGTGGGGCCTCGGGCCCCT 
GAR22-S394A 
sense: GCACCCCGGCCGCTCCGAGACGG 
anti-sense: CCGTCTCGGAGCGGCCGGGGTGC 
GAR22-T429A 
sense: CTGTCGGTCCCCGCCCCTGCCCGGCG 
anti-sense: CGCCGGGCAGGGGCGGGGACCGACAG 
 
Number in gene name indicates amino acid in human GAR22β sequence, S: Serine, T: 
Threonine, A: Alanine; red: exchanged nucleotides for point mutation. 
 
2.4 Cell culture  
2.4.1 Culture of cell lines 
Materials for cell culture were purchased from Invitrogen. For all cell lines 
heat-inactivated fetal calf serum (FCS; 30 min at 56°C) was used. Cells were 
grown in a humidified incubator at 37°C and 5% CO2.  
HeLa cells stably transfected with prTet-M2 containing a reverse tet regulator 
(kind gift of M.Gossen, Max Delbrück Center for Molecular Medicine, Berlin, 
Germany; referred to as HeLa-tet cells) were used as an inducible expression 
system (tet-ON) (Figure 2.2) (Gossen and Bujard, 1992). 
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Figure 2.2: Schematic representation of tetON inducible expression system 
 
HeLa-tet, NIH3T3, HEK293, Phoenix-ampho cells, Phoenix-eco cells were 
cultured in Dulbecco’s modified Eagle medium (DMEM) with 10% FCS, 2 
mM glutamine and 100U penicillin/ streptomycin. B16F1 cells were cultured 
in DMEM with 10% FCS, 4 mM glutamine and 100 U penicillin/streptomycin. 
Cells were maintained under semi-confluent conditions and split 1:10 at 
regular intervals with trypsin-EDTA (0.5%). Transfection or transduction of 
cells was done at 50% confluency. 
2.4.2 Culture of erythroid progenitor cells 
Human cord blood was taken from umbilical cord after full-term pregnancy 
and collected in syringes or blood bags containing heparin or CPD (citrat, 
phosphat, dextrose) as anticoagulant, respectively. Blood was processed 
within 3 hours after collecting. To separate mononuclear cells, a Ficoll density 
gradient was used. Briefly, blood was filter through a 70-µm cell strainer and 
diluted 1:5 with PBS. Ficoll (PAA, Pasching, Austria) was overlaid with 
blood/PBS mix and centrifuged for 20 min at 800 g. Centrifugation was 
stopped very gently and mononuclear cells at the interphase were harvested. 
Cells were then washed with PBS. For the first 5 days of culture, cells were 
kept under proliferation conditions at a density of 5x106 cells/ml. At day 5, 
Ficoll density gradient centrifugation was performed to remove dead cells and 
remaining erythrocytes. From day 6 to day 9, cells were kept at a density of 
1x106 cells/ml. At day 9, cells were transferred to differentiation conditions.  
The cells were kept in a humidified incubator at 37°C and 5% CO2. Media for 
SCF/Epo cell culture is based on DMEM and compositions are listed in Table 
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2.6. SCF/Epo cells were treated with T3 (1x10-7 M, Sigma), 9cRA (1x10-6M, 
Sigma) and/or TR inhibitor KB044146 (2x10-6 M, kind gift of Michael-Robin 
Witt, KaroBio, Sweden). For these cultures FCS was extensively deprived of 
T3 and retinoids by charcoal treatment (Samuels et al., 1979). 
 
Table 2.6: Media composition for SCF/Epo cell culture 
proliferation differentiation 
medium  cytokine medium cytokine 
15% (v/v) FCS 
(Boehringer, 
Mannheim, 
Germany) 
100 ng/ml SCF 
(cell supernatant) 
 
15% (v/v) FCS 
(Boehringer, 
Mannheim, 
Germany) 
1 µg/ml insulin 
(Noro Nordisk, 
Bagsvaerd, 
Denmark) 
15% (v/v) ddH20 1 U/ml Epo 
(Cilag, 
Schaffhausen, 
Switzerland) 
 1 U/ml Epo 
(Cilag, 
Schaffhausen, 
Switzerland)  
1% (w/v) 
deionized, 
delipidated, 
dialyzed BSA 
1 µM 
dexamethason 
(Dex, Sigma) 
1% (w/v) 
deionized, 
delipidated, 
dialyzed BSA 
 
1.9 mM sodium 
bicarbonate  
   
0.1 mM  
β-Mercaptoethanol 
(Sigma)  
 0.1 mM  
β-Mercaptoethanol 
(Sigma) 
 
0.128 mg/ml iron-
saturated human 
transferrin (Sigma)  
 0.128 mg/ml iron-
saturated human 
transferrin (Sigma)  
 
100 U/ml 
Pen/Strep 
(Invitrogen) 
 100 U/ml 
Pen/Strep 
(Invitrogen) 
 
 
Erythroid differentiation was assessed by determining the accumulation of 
hemoglobin in cytocentrifugation preparations stained with benzidine and 
histological dyes (Panzenbock et al., 1998) and by measuring the reduction in 
cell volume (CASY-1 cell counter and analyzer system, Schärfe Systems, 
Reutlingen, Germany). Photographs were taken with an Axioplan 2 
microscope (Carl Zeiss, Jena, Germany) using Scion digital camera CFW-
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1312C (Scion Corporation, Frederick, MD, USA). Image processing was done 
using Photoshop CS software (Adobe, San Jose, CA, USA).  
2.5 Transfection 
2.5.1 Transient transfection 
Transfection was carried out using (i) calcium-phosphate or (ii) cationic lipid 
transfection reagents (Fugene, Roche, Mannheim, Germany; Lipofectamine 
2000, Invitrogen; Ex-Gen, Fermentas) according to manufacture’s 
instructions. For transfection with calcium-phosphate, 20 µg of DNA was 
mixed with 62.5 µl of 2 M calcium chloride in a total volume of 500 µl. The 
suspension was added drop wise to 500 µl of 2x HBS (50 mM HEPES, 280 
mM sodium chloride, 1.5 mM sodium hydrogen phosphate, pH 7.08) while 
‘bubbling’ with a pipette; 500 µl were then added drop wise to cells in 10 ml 
media (10 cm culture dish). For cells in 6 cm or 15 cm dishes 250 µl or 1000 µl 
of transfection mix, respectively, was used. Medium was replaced 12 to 16 
hours later. Cells were examined for GFP expression by microscopy and 
further processed 24 to 36 hours later.  
HeLa-tet cells were stably transfected with pRevTre plasmids (with tet 
response element) containing GAR22α-GFP, GAR22β-GFP, GAR22C-GFP or 
GFP alone by calcium phosphate. Transfected cells were selected with  
800 µg/ml hygromycin. Bulk culture and single clones of transfected cells were 
tested for response to doxycycline by flow cytometry (2.8) and Western 
blotting (2.16). 
2.5.2 Stable transduction using recombinant retrovirus 
For transduction of SCF/Epo cells, Phoenix-ampho cells (Pear et al., 1993) 
were transfected with calcium phosphate mix (2.5.1) containing 12 µg 
pMSCV (2.2.1), 6 µg pVPack-GP and 6 µg pVPack-10A1 (Stratagene). Two 
days later virus supernatant was recovered and centrifuged at 560 g for 4 min 
to remove cell debris. Supernatant was concentrated using 80 µg/ml 
chondroitin sulphate C (CSC) and 80 µg/ml polybrene (Landazuri et al., 
2006) and cells were incubated with virus at day 6, 7 and 8 of culture (2.4.2). 
Cells were analyzed by flow cytometry during differentiation culture at 
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various time points as described below (2.8). Additionally, GFP positive cells 
were isolated by cell sorting (FACS Vantage SE, BD Biosciences) at day 9 of 
proliferation culture and at day 1 of differentiation culture (2.4.2), and RNA 
was prepared as described (2.3.1). Under some experimental conditions, 
SCF/Epo cells were selected with 2 µg/ml puromycin for 24 hours. 
Transduction of NIH3T3 cells was carried out using ecotrophic retrovirus. 
Briefly, phoenix-eco cells were transfected with pMSCV constructs (2.2.1), 
pVPack-GP and pVPack-eco (Stratagene) as described above. Collected virus 
supernatant and new medium was added to NIH3T3 cells in a ratio of 2:1 or 
4:3 and 16 µg/ml polybrene. Cell were washed after 24 hours post-
transduction and kept under selection pressure with 40 µg/ml puromycin for 
5 passages.  
2.6 Wound healing assay 
NIH3T3 cells stably expressing GAR22 constructs were seeded in 6 cm dishes 
and grown until full confluency. A wound was made with a pipette-tip and 
cells were washed two times with complete medium to remove loose cells. 
Pictures of the same field were taken after various periods of time (0, 3, 6, 9, 
12 and 24 hours). In between, cells were kept in the incubator (37°C, 5% 
CO2). Three to 4 pictures were taken for each time point and condition 
(Liang et al., 2007). The gap was analyzed by measuring the space between 
the cells at 5 different locations along the gap in one picture. Measurements 
were done using Graphic Converter software (Lemke Software, Peine, 
Germany).  
Alternatively, cells were seeded in a cell culture insert (ibidi, Martinsried, 
Germany) and grown until full confluency (3.5 x 104 cells in 70 µl per chamber 
of the insert). Removal of the insert generated a gap between two cell 
monolayers. Cells were either analyzed as described above or cell movement 
into the gap was followed by time-lapse microscopy (2.7). 
2.7 Time-lapse microscopy 
Transiently transfected B16F1 cells were seeded on laminin coated coverslips 
or glass bottom dishes. Briefly, coverslips were incubated with 25 µg/ml 
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laminin for at least 2 hours at 37°C and extensively washed with a washing 
buffer (50 mM Tris/HCl, pH 6.9, 150 mM sodium chloride) before seeding the 
cells. The coverslips were prepared for time-lapse microscopy of single cell 
analysis using an Axivert 200 microscope (Carl Zeiss) equipped with a heating 
chamber. When glass bottom dishes were used, the dishes were placed in a 
heated CO2 chamber. Pictures were taken every 15 sec for 2 to 3 hours and 
processed with DIAS software (Soll Technologies, Inc., Iowa City, IA, USA). 
This work was done in collaboration with Sara El Sayad and Heike Siegler 
(Institute for Biomedical Engineering, Cell Biology, RWTH Aachen University, 
Aachen, Germany).  
Time-lapse microscopy was also used to monitor wound closure in wound 
healing assay (2.6). Cells were prepared as described before and mounted in 
heated CO2 chamber in the Axivert 200 microscope (Carl Zeiss) equipped with 
a cooled, back-illuminated charge-coupled camera (Cascade, Roper Scientific 
Inc., USA). Pictures were taken every 5 min for 24 hours.  
2.8 Flow cytometry 
Expression of cell surface antigens was analyzed by flow cytometry. Data were 
collected with a FACScalibur device (BD Biosciences) and analyzed with 
CellQuest software (BD Biosciences) or FlowJo software (Tree Star, Inc., 
Ashland, OR, USA) as described before (Panzenbock et al., 1998). Briefly, 
SCF/Epo cells were collected after various time point and/or treatment, 
washed with FACS buffer (PBS/0.5% BSA) and unspecific binding sites were 
blocked with Venimmun (1:10; CLS Behring, Hattersheim am 
Main, Germany) for 10 min at 4°C. SCF/Epo cells were stained for single 
staining with the following antibodies: CD11a (1:50; HI111; BD Biosciences), 
CD33 (1:50; WM53; Chemicon International, Temecula, CA, USA), CD36 
(1:50; CB38; Pharmingen BD Biosciences), CD71 (1:50; Ber-T9; DAKO, 
Glostrup, Denmark), E-cadherin (1:100; HECD-1; R&D Systems, Minneapolis, 
MN, USA), Band 3 (CD233; 1:10; BRIC 6; IGBRL, Bristol, UK) (Southcott et 
al., 1999) and glycophorin A/B (CD235; 1:50; E3; Sigma). Anti-mouse 
antibody coupled with FITC was used as secondary antibody in 1:50 dilution. 
For cells which where not fixed, propidium iodide (PI) staining was included 
to monitor and exclude dead cells. SCF/Epo cells, which were transduced 
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with GFP retrovirus, were fixed with formaldehyde for 30 min at room 
temperature before antibody staining and washed with FACS buffer. Then, 
anti-mouse antibody coupled with PE was used as secondary antibody.   
For cell cycle analysis SCF/Epo cells were washed with PBS and incubated 
with 7AAD (10 µg/mL; Molecular Probes, Invitrogen) (Schmid et al., 2000) in 
saponin buffer (0.02% saponin, 5 mM EDTA, 0.5% BSA, 0.1% sodium citrat 
in PBS) for 30 min. Cells were then washed with washing buffer (5 mM 
EDTA, 0.5% BSA, 0.1% sodium citrat in PBS) and analyzed by flow 
cytometry. Data were processed by ModFit software (Verity Software House, 
Topsham, ME, USA).  
2.9 Cumulative BrdU assay 
SCF/Epo cells were transduced with GAR22α-GFP and GAR22β-GFP 
retrovirus as described in 2.5.2 and selected with puromycin (2 µg/ml) for 24 
hours. Cell debris was removed using “dead cell removal” kit (Miltenyi, 
Bergisch Gladbach, Germany). At day 1 of differentiation, Bromodeoxyuridine 
(BrdU; 10 µM) was added, cells were fixed at regular time intervals (every 2 
hours for 12 hours) by 70% ice-cold ethanol and incubated at 4°C for a 
minimum of 30 min. Staining was performed as described using BrdU 
antibody (1:50; MoBU-1; Biolegend Inc., San Diego, CA, USA) (Haydar et al., 
2000). Briefly, the cell suspension was centrifuged and ethanol was carefully 
aspirated. Cells were resuspended by adding 2N HCl/0.5% Triton X-100 drop 
wise while gentle vortexing and incubated for 30 min at room temperature. 
After incubation, cell suspension was centrifuged, and cell pellet was 
resuspended in 0.1 M sodium borate and washed in PBS-T/BSA (0.5% 
Tween 20, 1% BSA). Cells were incubated with BrdU antibody coupled with 
biotin and strepatvidin-APC as secondary antibody. After the staining, cells 
were resuspended in FACS-buffer (0.5% BSA in PBS) and incubated with PI 
for 15 min followed by flow cytometry analysis (2.8). The labeling index was 
plotted against the BrdU pulse time to obtain the cumulative labeling curve 
(Nowakowski et al., 1989). Tc and Ts, duration of cell cycle and S-phase, 
respectively, were calculated. The function y = ax + b representing a linear 
graph leads to the calculation for Tc = 1/a and Ts = b/a. 
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2.10 DNA microarray analysis 
DNA microarray analysis was performed as described before (Hacker et al., 
2003; Hieronymus et al., 2005). Data were normalized using MAS5 algorithm 
(scaled to 300) and further analyzed using GeneSpring (Agilent Technologies, 
Palo Alto, CA, USA) and BioConductur (Ihaka and Gentleman, 1996). 
Microarray data were submitted to GEO database (http://www.ncbi. 
Nlm.nih.gov/geo/; series accession number GSE 7579). The data were 
analyzed in collaboration with David Ruau (Institute for Biomedical 
Engineering, Cell Biology, RWTH Aachen University, Aachen, Germany). 
2.11 Immunofluorescence staining 
Cells were seeded on laminin-coated or uncoated coverslips. Depending on the 
antibody, cells were fixed with paraformaldehyde (PFA) or methanol. To fix 
cells with PFA, medium was aspirated and cells were incubated for 20 min 
with 4% PFA solution. Subsequently, cells were washed 3 times with 
cytoskeleton buffer (CB; pH 7.0; 10 mM PIPES, 150 mM sodium chloride, 5 
mM EGTA, 5 mM glucose, 5 mM magnesium chloride). Cells were 
permeabilzed by treatment with 0.2% Triton X-100 in PBS for 1 min and 
washed 3 times with TBS buffer (20 mM Tris/HCl, pH 7.5, 154 mM sodium 
chloride, 2 mM EGTA, 2 mM magnesium chloride).  
To fix cells with methanol, medium was aspirated, ice-cold methanol was 
carefully added and cells were incubated at –20°C for 4 min. Cells were then 
rehydrated 3 times for 5 min with TBS/0.1% Triton-X 100 and finally 
washed with TBS.  
Fixed cells were subjected to antibody staining with first antibody for 30 min 
at room temperature, following a washing step with TBS and incubated with 
fluorescence labeled secondary antibody (Molecular Probes, Invitrogen), as 
indicated, for 30 min at room temperature. Coverslips were mounted on slides 
with ProLong mounting medium (Molecular Probes, Invitrogen). The 
following first antibodies were used: EB1 (1:50; clone 5; BD Tranduction 
Laboratories, San Jose, CA, USA), tubulin (Y1/2; hybridoma supernatant). 
Secondary antibodies were anti-mouse Alexa-594 (1:200), anti-rat Alexa-594 
(1:200) or anti-rat-350 (1:50; Molecular Probes, Invitrogen). Fluorescent-
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labeled phalloidin (1:200; in Alexa-594 or Alexa-350; Molecular Probes, 
Invitrogen) was used for actin staining. Pictures were taken with an Axiovert 
200 microscope (Carl Zeiss) equipped with a cooled, back-illuminated charge-
coupled camera (Cascade, Roper Scientific Inc.) and processed using IPlab 
(BD Biosciences, Bioimaging, Rockville, MD, USA) and Photoshop CS 
programs. 
2.12 Nocodazole wash out assay 
NIH3T3 cells stably transfected (2.5.2) with GAR22-GFP variants, GFP or 
untransfected were seeded on uncoated coverslips and 24 hours later 
subjected to nocodazole wash out assay as described before (Marceiller et al., 
2005). Briefly, medium was replaced with pre-warmed medium containing 5 
µM nocodazole and cells were incubated at 37°C for 2 hour and 1 hour on ice 
to disassemble microtubule structures. Cells were kept on ice until recovery 
assay. Cells were washed 2 times with pre-warmed medium and left on a 
heating plate at 37°C for various periods of time (0, 3, 7.5, 10 and 30 min). 
After the time of microtubule recovery, cells were washed with pre-warmed 
microtubule stabilizing buffer (MSB; pH 6.9; 85 mM PIPES, 1 mM EGTA, 1 
mM magnesium chloride). Monomeric tubulin was extracted with MSB/0.5% 
Triton-X 100 for 3 min on a heating plate. Subsequently, cells were fixed with 
ice-cold methanol and further processed as described in 2.11. Microtubules 
were stained with Y1/2 antibody (hybridoma supernatant) and DNA with 
DAPI (20 µg/ml). Cells were analyzed by microscopy observing the reassemble 
of microtubules. At least 100 cells for each time point and experimental 
condition were counted. Cells were counted as positive, when the microtubule 
cytoskeleton was fully assembled. A percentage of positive cells were 
calculated.  
2.13 Cell lysate preparation for proteins 
Adherent cells were grown until 80% confluency. For lysis, cells were kept on 
ice, washed 2 times with cold PBS and lysed with sample buffer (12 mM 
Tris/HCl, pH 6.8, 5% glycerol, 0.4% SDS, 0.7 mM β-Mercaptoethanol, 0.02% 
Bromphenol Blue), which was added directly on the dish. Cells were scraped 
off the dish and transferred to a tube. Protein lysates of SCF/Epo cell were 
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washed twice with PBS and lysed with sample buffer. All protein lysates in 
sample buffer were heated for 5 min at 95°C. Lysates were kept at 4°C for 
short-term and -20°C for long-term stoarge until subjected to SDS-PAGE 
(2.15) and Western blotting (2.16).  
In experiments that required determination of protein concentration, cells 
were handled as described above and lysed with lysis buffer (50 mM 
Tris/HCl, pH 7.5, 150 mM sodium chloride, 10% glycerol, 1% NP-40, 1 mM 
EDTA, 1 mM DTT, 100 µM sodium vanadate, 14 µg/ml Aprotinin (Pierce, 
Thermo Scientific, Rockford, IL, USA), 2.5 µg/ml Leupeptin (Pierce), 0.5 mM 
PMSF) directly on the dish. In experiments scheduled for phosphatase 
treatment, lysis buffer was without EDTA and sodium vanadate. Cells were 
scraped off the dish and transferred to a tube, incubated for 30 min on ice 
and then centrifuged at 20.000 g for 30 min. Supernatant was transferred 
into a new tube, flash-frozen with liquid nitrogen and stored in -80°C until 
further usage. Protein concentration was determined by Bradford assay (Bio-
Rad, München, Germany).  
2.14 Immunoprecipitation 
Immunoprecipitation was done according to a protocol from Amersham, GE 
Healthcare. Briefly, 2.5-3 mg protein was used; lysate was cleared of unspecific 
binding by pre-incubation (1 hour at 4°C on rotating device) with washed 
Protein G beads (Amersham, GE Healthcare). Samples were centrifuged (500 
g for 2 min at 4°C) and supernatant was transferred into a new tube, 50 µl 
were kept as input control. GFP antibody (10 µl, clone 270F3, hybridoma 
supernatant), used as capture antibody, was added to the lysate and 
incubated for 1 hour at 4°C on rotating device. Later, washed Protein G 
beads were added to the samples and incubation was continued for another 
hour. To precipitate the protein, samples were centrifuged at 200 g for 2 min 
at 4°C. In some experiments, phosphatase treatment was applied to the 
precipitate. Briefly, beads were recovered in buffer compatible with alkaline 
phosphatase and 10 U of alkaline phosphatase (Fermentas) was added. 
Samples were incubated for 30 min at 37°C in a shaker. Phosphatase was 
inhibited by adding EDTA (f.c. 10 mM) and sodium vanadate (f.c. 1 mM). 
Beads with precipitate were then again incubated with cell lysate for 1 hour 
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at 4°C on rotating device. The second precipitation was carried out as 
described above. Beads were washed 3 times with lysis buffer and precipitated 
proteins were eluted in 30 µl sample buffer (80 mM Tris/HCl, pH 6.8, 25 mM 
DTT, 2% SDS, 10% glycerol; incubated for 5 min at 95°C), 15 µl were loaded 
on SDS gel and processed for Western blotting (2.16).  
2.15 SDS Polyacrylamid Electrophorese (SDS-PAGE) 
SDS gels were prepared using a Mini-Protean Tetra Cell apparatus (Bio-
Rad). Briefly, resolving gels were prepared of 5 ml H2O, 2.5 ml lower gel buffer 
(1.5 M Tris, pH 8.8, 0.4% SDS), 2.5 ml 40% acryl amid (Bio-Rad) and 50 µl 
10% ammonium per-sulfate (APS, Bio-Rad), 8.5 µl TEMED (Bio-Rad) for 
polymerization. Stacking gels contained 1.875 ml H2O, 2.5 ml upper gel buffer 
(0.25 M Tris, pH 6.8, 0.2% SDS), 0.625 ml 40% acryl amid and 25 µl 10% 
APS, 8.5 µl TEMED for polymerization. Gels were inserted in a tank with 
SDS running buffer (0.25 M Trizma Base, 1.92 M glycine, 1% SDS), and 
samples were loaded into wells. SDS-PAGE was carried out at 30 mA for 60 
min whit 2 gels running at the same time. Gels were subjected to coomassie 
staining or Western blotting.  
For coomassie staining, gels were incubated in fixation buffer (50% methanol, 
10% glacial acid) for 5 min, and then incubated in coomassie staining solution 
(0.025% Coomassie Brilliant Blue, 50% methanol, 10% glacial acid) for 
approximately 1 hour on rocking platform. To visualize the protein bands, 
gels were destained with destain-solution (45% methanol, 10% glacial acid) 
until the background was almost clear. The gel was then washed with H2O 
and scanned. Western blotting is described in 2.16. 
2.16 Western blotting 
Proteins in SDS gels were blotted on a membrane (PVDF; Pierce) by a semi-
dry blotting procedure. Briefly, filter paper, gel, and membrane were soaked in 
transfer buffer (48 mM Trisma Base, 39 mM glycine, 0.03% SDS, 20% 
methanol) and assembled. Blotting was carried out at 150 mA for 1.5 hours 
with a semi-dry blotting device (Multiphor II, Pharmacia Biotech, GE 
Healthcare). For immunolabeling, blots were blocked in 3% milk (delipidated 
dry milk; Nestle Carnation, USA) in TBS-T (25 mM Tris/HCl, pH 7.4, 147 
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mM sodium chloride, 2.7 mM potassium chloride, 0.1% Tween 20) over night 
at 4°C. Blots were incubated with first antibody in 3% milk/TBS-T for 1 
hour at room temperature, following 3 washing steps with TBS-T for 10 min 
each on a rocking platform. Blots were then incubated with secondary 
antibody coupled with Horseradish-peroxidase (Amersham, GE Healthcare) in 
3% milk/TBS-T for 1 hour at room temperature. After washing blots as 
before, blots were incubated with ECL reagent (Pierce) and exposed to film 
or developed with a chemiluminescence sensitive camera (LAS-3000, Fujifilm, 
USA). The following antibodies were used for lysates of SCF/Epo cells: c-kit 
(1:500; C-19; Santa Cruz Biotechnology, Santa Cruz, CA, USA), GATA-1 
(1:500; H2; kindly provided by R.H. Nicolas, The Institute for Cancer 
Research, Cancer Research UK, London), Epo receptor (1:500; Upstate, 
Millipore, Billerica, MA, USA), actin (1:3500; AC-74; Sigma), GAR22 (1:500; 
(Gamper et al., 2009)). For NIH3T3 or HeLa-tet lysates the following 
antibodies were used: EB1 (1:500; clone 5), GAR22 or actin. 
When binding affinity ratio was calculated tiff files of developed Western 
blots were analyzed in Image J (http://rsbweb.nih.gov/ij/) using gel analysis 
to calculate the area of band intensity. Then the ratio was calculated between 
the intensity of EB1 band to the respective GAR22 band.   
2.17 Tandem affinity purification (TAP assay) 
The vectors pcDNA5/FRT/TO/NTAP-GAR22β or –GAR22C were stably 
integrated in Flp-In-T-Rex 293 cells (Invitrogen, see manufacture’s protocol, 
kind gift from Bernhard Lüscher, Institute for Biochemistry, RWTH Aachen 
University, Aachen, Germany) and selected with antibiotics according to 
manufacture’s protocol. For protein expression cells were treated with 0.1% 
doxycycline for 16 hours. TAP assay was performed as described (Kleine et 
al., 2008; Puig et al., 2001). This work was done in collaboration with Henning 
Kleine (Institute for Biochemistry, RWTH Aachen University, Aachen, 
Germany) and David W. Litchfield (Department of Biochemistry, University 
of Western Ontario, London, Canada).  
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2.18 Protein purification 
2.18.1 GST tagged proteins 
BL21(DH3) bacteria were transformed with pGex4T1 vector containing 
GAR22 variants (see 2.2.1) and plated on agar containing 100 µg/ml 
ampicillin, a colony was picked, 50 ml starter culture was inoculated and 
grown over night at 37°C. The main culture (500 ml) was inoculated with 25 
ml of the starter culture and grown until an optical density OD600 of 0.5-0.7. 
Protein expression was induced with 1 mM IPTG and incubated over night at 
room temperature while shaking. Bacteria suspension was centrifuged at 5,000 
g for 15 min at 4°C. The pellet was frozen at -80°C and thawed again in 37°C 
water bath.  
For isolation of GST-tagged protein, the pellets were resuspended in 30 ml 
cold TNE buffer (20 mM Tris/HCl, pH 8.0, 150 mM sodium chloride, 1 mM 
EDTA (pH 8.0), 5 mM DTT, 0.5 mM PMSF, 14 µg/ml Aprotinin) and 
suspension was incubated with 6 mg lysozyme on ice for 30 min. The 
suspension was then sonicated 3 times with 30 pulses of a Branson sonifier 
and centrifuged at 10,000 g for 30 min at 4°C. The clear supernatant was 
transferred to a new tube and incubated with equilibrated Glutathione-
Agarose beads (Macherey & Nagel) for 1 hour at 4°C on a rotating device. 
Suspension was centrifuged at 500 g for 2 min at 4°C, supernatant was 
aspirated and beads were washed 3 times with cold PBS. Beads were 
resuspended in 1 ml PBS and transferred to an empty column (Bio-Rad), 
where they were washed with GST washing buffer (100 mM Tris/HCl, pH 
8.0, 120 mM sodium chloride). GST tagged protein was eluted 3 times with 
300 µl GST elution buffer (20 mM glutathione in GST washing buffer). GST 
elution buffer was incubated on the beads for 5 min at 4°C before recovering 
eluate in a tube. To analyze the fractions, 2 µl aliquots were separated by 
SDS-PAGE (2.15) and gel was stained with coomassie. 
2.18.2 His tagged proteins 
BL21(DH3) were transformed with pET-EB1-GFP (kind gift from Tim 
Noetzel, Max Planck Institute, Dresden, Germany; for vector map see 6.3) and 
processed, as in 2.18.1. The bacteria pellet was resuspended in IMAC lysis 
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buffer (20 mM HEPES, pH 7.5, 10% glycerol, 300 mM sodium chloride, 0.1% 
NP-40, 5 mM Imidazol, 14 µg/ml Aprotinin, 0.5 mM PMSF, 1 µg/ml 
Pepstatin A, 2 mM β-Mercaptoethanol) and suspension was incubated with 
lysozyme and sonicated as before. The supernatant was incubated with 
equilibrated TALON beads (Clontech) for 1 hour at 4°C on rotating device. 
Bead suspension was centrifuged at 500 g for 2 min at 4°C and washed 3 
times with IMAC lysis buffer. The supernatant was aspirated and beads were 
incubated with 500 µl IMAC elution buffer (20 mM HEPES, pH 7.5, 10% 
glycerol, 200 mM sodium chloride, 0.1% NP-40, 10 mM EDTA, 10 mM DTT, 
14 µg/ml Aprotinin) for 10 min at 4°C on a rotating device. The suspension 
was centrifuged at 500 g for 2 min at 4°C and the supernatant containing the 
eluted proteins were transferred to a new tube. The elution step was repeated 
2 more times. To analyze the fractions, 2 µl aliquots were separated by SDS-
PAGE (2.15) and gel was stained with coomassie. 
2.19 GAR22 antibody purification 
This work was done in collaboration with Petr Bartunek and David Sedlak 
(Institute for Molecular Genetics, Prague, Czech Republic). Briefly, pGex-
GAR22-PB vector kindly provided by Petr Bartunk, was used to prepare a 
protein fragment of GAR22 for antibody production (Gamper et al., 2009). 
GST-GAR22-PB protein was prepared as described in 2.18.1. To purify serum 
containing GAR22 antibody, GST-GAR22-PB was coupled to Glutathione-
agarose beads (Sigma, swollen in water over night and washed with lysis 
buffer: 25 mM Tris/HCl, pH 8.0, 150 mM sodium chloride, 1 mM EDTA, 1 
mM DTT, 1% Triton X-100) by incubating protein supernatant with beads. 
Supernatant and coupled glutathione-agarose were washed 3 times with lysis 
buffer for 5 minute at 4°C, 2 times with lysis buffer with 500 mM sodium 
chloride for 5 minute at room temperature and 1 time using lysis buffer for 5 
min at room temperature. Next, GST-GAR22-PB proteins were covalently 
bound to Glutathione-agarose beads. Therefore, the complexes were washed 2 
times with borate buffer (200 mM borate sodium hydroxide, pH 8.6) for 5 
minute at room temperature, then 3 ml of DMP (200mM tri-ethanolamine, 
pH 8.3, 15.5 mg/2 ml dimethyl pimelimidate-HCl) were added to the beads 
and incubate for 30 minute at room temperature on rotating device, 
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centrifuged gently, and supernatant was aspirated. Then, 10 ml of 
ethanolamine were added and incubate for 60 minute at room temperature, 
washed 2 times with glycine acid buffer (100 mM glycine, pH 2.5) for 3 
minute at room temperature, and 1 time with TBS. To purify GAR22 
antibody, collected serum was diluted 1:2 with TBS, the prepared GST-
GAR22-PB-gluthathione-agarose complexes were added and incubated over 
night at 4°C on a rotating device. Then, agarose beads were washed 5 times 
with ice cold TBS and once with 1:10 diluted TBS, centrifuged gently and 
supernatant was aspirated. To elute antibodies 1 ml glycine acid buffer was 
added, incubated for 5 minutes at room temperature while shaking, 
centrifuged, and supernatant containing antibodies were transferred into a 
new tube. Elution was repeated 1 more time. The antibody solution was 
adjusted to a pH of 7.0-8.0, protein concentration was measured by Bradford 
(Bio-Rad) and aliquots were flash-frozen. The antibody was tested by 
Western Blotting (2.16). 
2.20 In vitro pull down 
Purified GST-GAR22 protein and His-EB1-GFP protein were incubated with 
Glutathione-Agarose beads in pull down buffer (20 mM HEPES, pH 7.4, 50 
mM sodium chloride, 1.5 mM EDTA, 0.1% NP-40, 14 µg/ml Aprotinin, 1 
mg/ml Pefablock, 1 µg/ml Pepstatin A, 2.5 µg/ml Leupeptin) for 3 hours at 
4°C on rotating device. The suspension was centrifuged at 500 g for 2 min at 
4°C and washed 3 times in pull down buffer. The proteins bound to the 
beads were eluted in sample buffer, heated at 95°C for 5 min, resolved by 
SDS-PAGE (2.15), and detected by Western blotting (2.16) using EB1 
antibody. 
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3 Results 
3.1 Red blood cell differentiation in vitro 
Mononuclear cells from human umbilical cord blood were isolated and 
cultured with SCF, Epo and Dex (referred to as proliferation conditions), 
which gave rise to Epo-dependent progenitors (named SCF/Epo progenitor 
cells) of BFU-E and CFU-E corresponding cell types. Cells under proliferation 
conditions showed logarithmic growth until day 13 of culture (Figure 3.1A, 
left panel). When switched to differentiation conditions (Epo and insulin) at 
day 9 of culture, cells ceased proliferation 2 days later accompanied by 
reduction of cell volume (Figure 3.1A, right panel). Furthermore, 
differentiating cells progressively accumulated hemoglobin as determined by 
benzidine staining (Figure 3.1B). SCF/Epo progenitor cells differentiated for 4 
to 5 days, where already enucleated cells were observed.   
At the beginning of differentiation an average of 86.8% and 83.5% of 
SCF/Epo progenitors expressed CD36 and CD71, respectively, and 78.4% of 
the cells expressed E-cadherin. In contrast, only approximately 5.4% and 
13.9% of the cells expressed the differentiation markers Band 3 and 
glycophorin A/B, respectively (Figure 3.1C and Figure 3.2A). In addition, 
6.1% and 3.9% of the cells expressed CD11a or CD33, respectively, which are 
markers for the myeloid lineage (Figure 3.2A). After 4 days of differentiation, 
the expression of Band 3 and glycophorin A/B increased to an average of 
74.4% and 68.3% (Figure 3.2B). At the same time, cells expressing CD71 
decreased concomitantly with a reduction in the mean fluorescence intensity 
of CD71 (Figure 3.1C and Figure 3.2A). Thus, SCF/Epo cells are efficiently 
expanded and, in a second step, terminally differentiated to mature 
erythrocytes. 
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Figure 3.1: Differentiation of SCF/Epo cells 
SCF/Epo cells were amplified in proliferation conditions with SCF+Epo+Dex and subjected to 
differentiation with Epo+insulin. (A) Cumulative cell number (logarithmic scale) and cell 
volume (in femtoliter) of SCF/Epo cells were determined after various periods of time. 
Average values of 3 experiments are shown. (B) SCF/Epo progenitor cells under proliferation 
and differentiation conditions were subjected to cytocentrifugation, stained for hemoglobin 
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with benzidine and photographed. (C) Representative flow cytometry profile of SCF/Epo 
progenitor cells under proliferation and differentiation conditions for various surface markers. 
Filled histogram indicates negative control; open histogram represents antibody stained 
samples. 
 
 
 
Figure 3.2: Kinetics of surface marker expression during SCF/Epo cells differentiation 
SCF/Epo cells were subjected to differentiation with Epo+insulin and analyzed for surface 
marker expression by flow cytometry. (A) Average expression of CD36, CD71, E-cadherin (E-
cad), Band 3 and glycophorin A/B (glyA/B) at day 0 (left panel) and day 4 (right panel) of 
differentiation. (B) Kinetics of average expression of Band 3 (left panel) and glycophorin A/B 
(right panel) during proliferation (SCF+Epo+Dex) and differentiation (Epo+insulin) of SCF/Epo 
progenitors. Time points are indicated. Average values of at least 3 experiments are shown. 
Box and whiskers plot: the line in the middle of the box indicates the median; the top of the 
box indicates the 75th percentile, whereas the bottom of the box indicates the 25th percentile. 
Whiskers represent the 10th (lower) and 90th (upper) percentile, respectively.     
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3.2 Thyroid hormone accelerates red cell differentiation in vitro 
The oncogenic TR version v-erbA causes a fatal erythroleukemia in birds 
(Beug et al., 1994) and blocks red cell differentiation in vitro (Disela et al., 
1991; Schroeder et al., 1992; Zenke et al., 1988; Zenke et al., 1990). SCF/Epo 
progenitor cells express TRα1, TRα2, RARα, RXRα and RXRβ, as well as 
multiple co-activators, such as NcoA1, NcoA2 and TRAP220 (Gamper et al., 
2009), which are known to interact directly with nuclear receptors. Thus, the 
impact of ligand-activated TR on red blood cell differentiation was assessed. 
SCF/Epo progenitor cells were differentiated with Epo+insulin in the 
presence or absence of T3, 9cRA or T3+9cRA and analyzed for cell number, 
cell volume and morphology (Figure 3.3). Importantly, T3 and 9cRA 
effectively accelerated differentiation as displayed by a reduction in cell 
proliferation and cell volume and an increased hemoglobinization. Hemoglobin 
staining with benzidine on cytocentrifugation preparations of SCF/Epo cells 
at day 4 of differentiation revealed a higher number of hemoglobin-containing 
cells with condensed nucleus when cells were treated with T3, 9cRA or 
T3+9cRA (Figure 3.3B). Moreover, it was found that T3 alone was more 
effective than 9cRA alone, whereas a simultaneous treatment with T3 and 
9cRA was slightly more efficient than T3 alone (Figure 3.3A and B).  
Next, morphologically different erythroblast stages from cytocentrifugation 
preparations stained for hemoglobin were analyzed: Proerythroblasts, the 
most immature erythroblasts, were identified as large, round and purple 
stained cells, followed by basophilic erythroblasts, which started to synthesize 
hemoglobin, but did not show nuclear condensation or reduction in cell size. 
Polychromatic erythrobloasts exhibited a brighter red staining for increased 
hemoglobin content, but the nucleus was not yet condensed. Orthochromatic 
erythroblasts showed a very condensed nucleus and notable reduction in cell 
size. Reticulocytes or erythrocytes extruded their nucleus. The analysis 
revealed that the frequencies of poly- and orthochromatic erythroblasts 
increased in response to T3, already starting after 2 days of differentiation 
(Figure 3.3C). In cultures of SCF/Epo cells at day 4 of T3 treatment, no 
early erythroblast cells were observed, whereas in the absence of T3 more 
than 20% of proerythroblasts were found (Figure 3.3C).   
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Figure 3.3: T3 accelerates red cell differentiation in vitro 
SCF/Epo cells were differentiated with Epo+insulin in the presence of T3, 9cRA, or T3+9cRA. 
(A) Cumulative cell number and cell volume of differentiating SCF/Epo cells were determined 
after various periods of time. Average values of 3 experiments are shown. (B) Cells before 
(day 0) and 4 days after differentiation induction were subjected to cytocentrifugation and 
hemoglobin staining by benzidine and photographed. (C) Distribution of various differentiation 
levels of erythroblast cells shown in (B). Average values of 3 independent experiments are 
shown.  
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To further extend these observations, differentiating cells treated with T3, 
9cRA, or T3+9cRA or left untreated were analyzed for expression of cell 
surface molecules, including E-cadherin, Band 3 and glycophorin A/B (Figure 
3.4A and data not shown). Band 3 expression was upregulated by T3 but not 
by 9cRA, and there was no further upregulation following simultaneous 
treatment with T3 and 9cRA. Interestingly, E-cadherin expression was 
dramatically reduced in cells treated with T3. At day 4 of differentiation with 
T3 only 5% of the cells expressed E-cadherin compared to 53% of untreated 
SCF/Epo cells expressing E-cadherin. Additional treatment with 9cRA did 
not further downregulate E-cadherin expression (Figure 3.4A). Furthermore, 
differentiating cells were analyzed for cell cycle distribution by 7AAD staining. 
It demonstrated that hormone treatment enhanced the number of cells in 
G0/G1 phase at day 4 of differentiation (Figure 3.4B and C). This effect was 
most pronounced for T3 and T3+9cRA. Thus, T3 and 9cRA effectively 
accelerated terminal differentiation and caused growth inhibition of human 
erythroid cells in vitro. 
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Figure 3.4: T3 accelerates red cell differentiation 
SCF/Epo cells were cultured under differentiation conditions with T3, 9cRA, or T3+9cRA or 
left untreated. (A) Flow cytometry analysis of E-cadherin (left panel) and Band 3 (right panel) 
expression after 2 and 4 days of differentiation. Filled histogram indicates negative control; 
open histogram represents antibody stained samples. (B) Cell cycle profile of SCF/Epo cells 
differentiated with T3, 9cRA or T3+9cRA or left untreated, stained with 7AAD and analyzed by 
flow cytometry. (C) Quantification of cells in G0/G1 at day 0, 2 and 4 of differentiation with T3, 
9cRA and T3+9cRA. Cells were stained as in (B) analyzed by Modfit software. Average 
values of 3 independent experiments are shown (asterisks indicate p-value <0.0001).  
 
52    RESULTS 
 
 
3.3 Gene expression profiling identified GAR22 
The differentiation stimulus provided by ligand-activated TR might be due to 
(i) an overall increase in gene expression normally involved in canonical red 
blood cell differentiation or (ii) the expression of distinct sets of genes, which 
lead to an accelerated differentiation by an additional or alternative program. 
To investigate this hypothesis, SCF/Epo cells were induced to differentiate 
with or without T3+9cRA (8, 24, 48 hours), RNA was prepared and 
subjected to gene expression profiling with DNA microarrays (Affymetrix, 
Santa Clara, CA, USA) containing probe sets for about 12,000 human genes. 
Differentiating SCF/Epo cells receiving single treatments of T3 or 9cRA (8 
hours) were analyzed as well to determine the contribution of individual 
ligands. Untreated cells were used as control. 
In all samples analyzed, 40-48% of the genes were found to be expressed. Lists 
of differentially regulated genes were generated comprising of genes that were 
induced or repressed by more than two-fold following T3+9cRA treatment 
with respect to (i) undifferentiated cells (0 hour of differentiation, gene list I, 
see Supplementary Material (Gamper et al., 2009)) or (ii) the respective 
untreated cells (8, 24, 48 hours of differentiation, gene list II, see 
Supplementary Material (Gamper et al., 2009)). 
T3+9cRA regulated genes (gene list I) were subjected to hierarchical cluster 
analysis and results were displayed in heatmap format (Figure 3.5). SCF/Epo 
cells at 8 hours of differentiation with or without hormone treatment 
clustered close to undifferentiated cells. Maximal changes in gene expression 
were observed at 24 and 48-hour time point of T3+9cRA treated cells.  
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Figure 3.5: Hierarchical cluster analysis of T3 treated SCF/Epo cells 
The impact of T3+9cRA on red cell gene expression was assessed by gene expression 
profiling with Affymetrix GeneChip arrays (HG-U95Av2). SCF/Epo cells were differentiated 
with and without T3+9cRA for 0, 8, 24 and 48 hours (hrs) and subjected to microarray 
analysis. Differentially regulated genes with more than two-fold increase or decrease upon 
T3+9cRA treatment with respect to cells prior to differentiation (1495 genes) were analyzed by 
hierarchical clustering and depicted in heatmap format: red, high expression; white, 
intermediate expression and blue, low expression. Individual gene clusters of differentially 
regulated genes are indicated (clusters 1-6).  
 
I then proceeded to compile genes, which were differentially regulated (more 
than two-fold) by T3+9cRA at 8, 24 and 48 hours of differentiation (gene list 
II). Genes were subjected to hierarchical cluster analysis and results were 
displayed in heatmap format (Figure 3.6). It was found that untreated cells 
group together and treated cells formed a separate cluster. This analysis also 
showed a prominent cluster of 150 genes with low expression in untreated 
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cells and a strong induction after 8 and 24 hours of T3+9cRA treatment 
(Figure 3.6B). Given the observation that T3 alone had a major impact on 
red cell differentiation, these 150 genes were intersected in Venn diagram with 
a list of genes that were induced by T3 after 8 hours of treatment. This 
allowed the identification of 43 genes, which included 6 genes that showed 
robust responses to T3 treatment only, including genes that encode enzymes, 
signalling molecules, transcription factors and growth regulators (Table 3.1). 
 
 
Figure 3.6: Hierarchical cluster analysis of T3 treated SCF/Epo cells 
The impact of T3+9cRA on red cell gene expression was assessed by gene expression 
profiling with Affymetrix GeneChip arrays (HG-U95Av2). SCF/Epo cells were differentiated 
with and without T3+9cRA and subjected to DNA microarray analysis. (A) Hierarchical cluster 
analysis of T3+9cRA induced genes with  more than two-fold increase or decrease with 
respect to untreated cells at 8, 24 or 48 hours (hrs) of differentiation (1857 genes) and 
depicted in heatmap format: red, high expression; white, intermediate expression and blue, 
low expression. (B) Enlarged representation of cluster with strong upregulation within 8 and 
24 hours of T3+9cRA treatment.  
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Table 3.1: Gene list extracted from hierarchical cluster analysis from gene list II 
Category Gene name Gene symbol GeneID 
Fructose-1,6-bisphosphatase 1 FBP1 2203 Enzymes 
Hemopoietic cell kinase HCK 3055 
Krüppel-like factor 9 KLF9/BTEB1 687 Transcription 
factors Interferon regulatory factor 1 IRF1 3659 
Signal transduction  Src-like-adaptor SLA 6503 
Cell growth Growth arrest-specific 2 like 1 GAS2L1/GAR22 10634 
 
In further analysis I focused on BTEB1 (basic transcription element binding 
protein 1) encodes a zinc finger transcription factor and has already been 
shown to be directly regulated by T3 (Denver et al., 1999), and on a novel T3 
target gene, GAR22 (also referred to as GAS2L1; (Gamper et al., 2009). 
Northern blotting shows that SCF/Epo cells express the 2.7 kb GAR22β 
variant (Figure 3.7). 
 
 
 
Figure 3.7: SCF/Epo cells express GAR22β  variant 
SCF/Epo cells were cultured with Epo+insulin and treated with T3 (10-7M) for 8 hours and 
analyzed for GAR22 expression by Northern blotting. 18S rRNA is shown as loading control. 
(in collaboration with Ki-Ryang Koh, Institute for Biomedical Engineering, Cell Biology, RWTH 
Aachen University, Aachen, Germany) 
 
To further investigate these observations, quantitative RT-PCR was used to 
analyze GAR22 and BTEB1 expression in response to T3 treatment (Figure 
3.8). In this series of experiments a panel of red blood cell genes were included, 
such as Epo receptor, ALAD and the transcription factors GATA-1, GATA-
2, EKLF and LMO2. Relative expression levels of target genes were subjected 
to hierarchical clustering and depicted in heatmap format (Figure 3.8). This 
analysis revealed distinct gene expression pattern in response to T3. GATA-2 
and c-kit expression was downregulated during red blood cell differentiation 
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and this downregulation was enhanced by T3 treatment (Figure 3.8). GATA-
1, Epo receptor and ALAD were upregulated but were not affected by T3. 
GAR22 and BTEB1 were effectively induced by T3, but were unchanged 
during differentiation without T3. Expression of the cdk inhibitors p21, p27 
and p57 was more complex: a transient increase of p21 and p27 was observed 
after 12 and 18 hours. Expression of p21 was upregulated after 4 days of 
differentiation both, in the presence and absence of T3, while expression of 
p27 remained essentially unchanged (Figure 3.8D).  
RT-PCR data were also displayed quantitatively as fold change in response to 
T3 (Figure 3.8C). These data demonstrate an effective downregulation of 
GATA-2, LMO2 and c-kit by T3, while there was a prominent upregulation 
of GAR22 and BTEB1. Western blot analysis further supported these 
observations (Figure 3.9A). Expression of GAR22 protein was efficiently 
upregulated by T3. The expression of GATA-1, Epo receptor and c-kit was 
virtually unchanged. 
To investigate whether GAR22 represents a direct target of TR, SCF/Epo 
cells were treated with T3 in the presence or absence of the protein 
biosynthesis inhibitor cycloheximide and extracted RNA was analyzed by RT-
PCR (Figure 3.9B). GAR22 was induced within 8 hours by T3 even in the 
presence of cycloheximide similar to BTEB1, indicating that GAR22 is a direct 
target of TR, GATA-2 and c-kit used as control were unaffected by T3 
(Figure 3.9B). To further extend this observation, SCF/Epo cells were treated 
with and without T3 and TR inhibitor KB044146. The TR inhibitor 
suppressed T3 induced upregulation of GAR22 (Figure 3.9C), providing 
further support for GAR22 as a direct target of TR. 
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Figure 3.8: The impact of T3 on red cell gene expression 
SCF/Epo cells were induced to differentiate with Epo+insulin with or without T3 for various 
periods of time (4, 8, 12, 18 and 24 hours). (A) Samples were subjected to semiquantitative 
RT-PCR and analyzed in agarose gels. Lane 12, no input cDNA control. (B) The samples 
shown in (A) were also analyzed by quantitative RT-PCR (TaqMan) and relative expression 
values were calculated using 2-ΔΔCt equation, Ct was evaluated with respect to 0 hour time 
point. Log2 values were analyzed by hierarchical clustering and depicted in heatmap format 
using “R” software: red, high expression; white, intermediate expression and blue, low 
expression. T3 induced GAR22 and BTEB1 expression and caused a more rapid 
downregulation of c-kit and GATA-2 (boxes). (C) Quantitative RT-PCR as described in (B). Ct 
values refer to the change in each time point with T3 vs. without T3. Log2 scale was applied 
and displayed as bar diagrams. Time points are indicated. A representative experiment is 
shown. Dotted line indicates background levels. (D) SCF/Epo cells were differentiated with or 
without T3 and analyzed by PCR at day 0, 2 and 4. Actin was used as loading control. 
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Figure 3.9: GAR22β  is a direct target gene of thyroid hormone receptor 
SCF/Epo cells were induced to differentiate with Epo+insulin with or without T3. After various 
periods of time (4, 8, 12, 18 and 24 hours) protein samples were subjected to Western blot 
analysis. Actin was used as loading control. Note the prominent T3 dependent induction of 72 
kDa GAR22 protein. Asterik: 70 kDa band of unknown identity recognized by GAR22 
antibody. (B) SCF/Epo cells were cultured with Epo+insulin and treated with T3 for 8 hours in 
the presence or absence of the protein synthesis inhibitor cycloheximide (CX, 20 µg/ml). Cells 
were analyzed by semi-quantitative RT-PCR. Lane 5, no input cDNA control. (C) SCF/Epo 
cells were cultured as described in (A) in the presence or absence of T3 (0.5 nM) and TR 
inhibitor KB044146 (2 µM) for 8 hours. Cells were analyzed for expression of GAR22 by 
quantitative RT-PCR. Actin was used for normalization. Average values of triplicates and fold 
change relative to untreated cells are shown. 
 
3.4 Ectopic expression of GAR22 in SCF/Epo cells  
To determine the impact of GAR22 on erythroid gene expression and 
differentiation, SCF/Epo cells were transduced with GAR22α-GFP and 
GAR22β-GFP retroviruses. Cells, kept under proliferating conditions or 
induced to differentiate, were analyzed for surface marker expression by flow 
cytometry. GAR22-GFP+ SCF/Epo cells expressed CD36, CD71 and Band 3 
comparable to control (GFP alone) or untransduced cells during proliferation 
or differentiation (Figure 3.10). 
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Figure 3.10: Ectopic GAR22 expression leaves differentiation unaffected  
SCF/Epo progenitors were transduced with GAR22α-GFP or GAR22β-GFP retroviruses and 
either subjected to proliferation conditions with SCF+Epo+Dex or differentiation conditions 
with Epo+insulin. GFP containing virus and untreated cells (wild type, WT) were used as 
control. Flow cytometry analysis of GFP+ cells expressing CD36, CD71 and Band 3 at day 9, 
11 and 13 of proliferation or day 0, 2 and 4 of differentiation. Filled histogram indicates 
negative control; open histogram represents antibody stained samples. One representative 
experiment out of 3 is shown. 
 
In addition, GAR22-GFP transduced cells showed an increase of the 
differentiation marker Band 3 over time during differentiation as seen in GFP 
control or untreated cells (Figure 3.10 and Figure 3.11). Furthermore, GFP+ 
cells at day 0 and 1 of differentiation were obtained by cell sorting and 
expression of GAR22 in transduced cells was verified by quantitative RT-PCR 
(Figure 3.11B and C). Samples were then analyzed by quantitative RT-PCR 
with a selection of red cell genes as in Figure 3.8 and subjected to hierarchical 
cluster analysis depicted in heatmap format (Figure 3.11D). It was observed 
that GAR22 variants (GAR22α and GAR22β) caused a more pronounced 
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downregulation of GATA-2 and c-kit than GFP control. Expression of several 
red blood cell genes, such as GATA-1, EKLF, Epo receptor and ALAD, were 
unaffected. Thus, ectopic GAR22 expression in SCF/Epo cells caused a similar 
expression pattern of analyzed genes than T3 treated cells. Moreover, the 
influence of GAR22 on cell growth was investigated by cumulative BrdU 
incorporation assay. GAR22β-GFP transduced SCF/Epo cells showed a 
lengthened cell cycle and S phase (36.4 hours versus 23.1 hours of control; 7.5 
hours versus 3.2 hours of control, respectively, average value of 2 experiments; 
Figure 3.11E). Thus, GAR22 expression caused reduced proliferation of 
SCF/Epo cells and thus might represent an important trigger of growth 
inhibition induced by thyroid hormone in these cells. 
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Figure 3.11: Ectopic GAR22 expression leaves differentiation unaffected and lengthens 
cell cycle in SCF/Epo cells  
SCF/Epo progenitors were transduced with GAR22α-GFP or GAR22β-GFP retroviruses and 
differentiated with Epo+insulin. (A) Flow cytometry analysis of GFP+ cells expressing Band 3 
at day 0, 2 and 4 of differentiation as indicated. Average values of 3 independent experiments 
are shown. (B) GFP+ cells were sorted (day 0 and day 1 of differentiation culture). Flow 
cytometry analysis before and after cell sorting of GAR22-GFP transduced cells (left and right 
panel, respectively). (C) Quantitative RT-PCR analysis of GAR22α-GFP and GAR22β-GFP 
transduced SCF/Epo cells (sorted for GFP+ cells). GFP retrovirus transduced cells were used 
as control. (D) Data of quantitative RT-PCR analysis were subjected to hierarchical cluster 
analysis and depicted in heatmap format: red, high expression; white, intermediate 
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expression; blue, low expression. Average values of dublicates are shown. (E) SCF/Epo cells 
were transduced with GAR22β-GFP retrovirus and GFP control virus, and subjected to 
cumulative BrdU incorporation assay. BrdU index was measured by flow cytometry and 
duration of cell cyle (Tc) and S-Phase (Ts) were calculated. One representative experiment is 
shown. 
 
3.5 GAR22 co-localizes with actin 
It has been shown that GAR22 binds to microfilaments and microtubules in 
vitro (Goriounov et al., 2003) suggesting that it might be involved in 
regulation of cell motility. This study, therefore, also aimed at characterizing 
the role of GAR22 in this process. To this end, GAR22-GFP fusion constructs 
were cloned and used to study the localization and dynamics of GAR22 
(Figure 3.12). Additionally, a GFP fusion construct was generated encoding 
for the carboxy-terminal part of GAR22 (referred to as GAR22C) separately 
(Figure 3.12). B16F1 mouse melanoma cells, were chosen as model, because 
these cells are highly motile and form distinct lamellipodia on laminin. The 
ectopic expression of the GAR22-GFP fusion proteins in B16F1 cells revealed 
a co-localization of GAR22α and GAR22β with actin (Figure 3.13.A). By 
contrast, GAR22C was mainly located in the nucleus and did not show any 
particular structure in the cell (Figure 3.13A). Cells with low expression level 
indicated by GFP expression were considered. Moreover, the dynamics of 
GAR22β were analyzed in transfected B16F1 cells by live cell imaging. The 
dynamics of GAR22β was similar to that of actin (Figure 3.13B) suggesting 
that this protein contributes to the regulation of actin cytoskeleton dynamics 
during cell motility.  
 
 
Figure 3.12: Schematic representation of GAR22-GFP fusion variants 
Scheme representing protein sequence of GAR22 varinats: CH: calponin homologue domain; 
GAR: GAR domain; GFP: green fluorescence protein; GAR22β: amino acid sequence from 1 
to 682; GAR22α amino acid sequence from 1 to 337, GAR22C amino acid sequence from 
319 to 682 
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Figure 3.13: Co-localization of GAR22α  and GAR22β  with actin 
B16F1 cells were transfected with GAR22α, GAR22β and GAR22C GFP fusion constructs, 
seeded on laminin and stained for actin with fluorescent-labeled phalloidin. White boxes 
indicate the frame, which is enlarged in the respective picture below. (B) To study the 
dynamics, B16F1 cells were transfected with GAR22β, plated on laminin and observed by 
time-lapse microscopy. Indicated time (t) is in minutes. Fluorescent picture is on the left, 
phase contrast (PHZ) picture is on the right. Scale bars represent 10 µm, arrowheads point to 
actin spots and filopodial structures in cells. 
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3.6 Overexpression of GAR22β impairs cell motility 
Next, the potential influence of GAR22 on cell motility was tested. First, a 
wound healing assay (2.6) was considered, which gives the possibility to gain 
a macroscopic idea of cell behavior. In this assay, a sub-population of cells was 
observed for the time it needed to close a wound in a monolayer. For a side-
by-side comparison of morphology and speed, one side of the wound 
contained transfected cells, whereas the other side contained untransfected 
cells. Immortal cells in a confluent monolayer loose cell polarity and stop 
proliferation. When a wound is applied in such monolayer, cells at the wound 
edge regain polarity and eventually move into the wound, as seen for 
untransfected NIH3T3 cells (Figure 3.14). Control cells needed approximately 
20-22 hours to reach the middle of the wound. Cells expressing GAR22β 
displayed a significant slower migration compared to GFP control cells or 
untransfected cells (Figure 3.15). Moreover, cells expressing GAR22α were 
slower than untransfected cells, although not to the same extent as GAR22β 
expressing cells (Figure 3.14; Figure 3.15). Observations of live cell imaging 
pictures revealed that NIH3T3 cells have an elongated shape with small 
protrusions for directional movement. Cells expressing GAR22β had a 
different behavior. The single cells were more spread at the surface and the 
cell protrusions did not point in the direction of movement for most of the 
time, suggesting that they have partially lost the ability to move along a given 
direction.  
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Figure 3.14: Overexpression of GAR22β  impairs cell motility 
NIH3T3 cells were stably transfected with GAR22-GFP fusion constructs and subjected to 
wound healing assay. For a direct comparison of morphology and speed of the cells one side 
of the wound were transfected cells, the other untransfected cells as indicated by the 
fluorescent picture in the top row. Cell motility was observed by time-lapse microscopy. Scale 
bar represents 100 µm, indicated time (t) is in hours, and arrows at the bottom of the figure 
indicate estimated distance traveled by the cells.   
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Figure 3.15: GAR22β  expressing cells exhibit impaired cell motility 
NIH3T3 cells were stably transfected with GAR22-GFP fusion constructs and subjected to 
wound healing assay. Statistical analysis of wound closing was done as followed, pictures of 
the same area of the wound were taken at the beginning and after 24 hours and distance was 
measured with Graphic converter software. Box and whiskers plot: the line in the middle of the 
box indicates the median; the top of the box indicates the 75th percentile, whereas the bottom 
of the box indicates the 25th percentile. Whiskers represent the 10th (lower) and 90th (upper) 
percentile, respectively. Asterisks indicate p-value <0.0001. 
 
Next, single cell analysis was done using B16F1 cells transiently expressing 
GAR22 variants or GFP as control (Figure 3.16). B16F1 cells are highly 
motile and have a distinct cell morphology and behavior on laminin. For the 
analysis of single cell motility, parameters such as speed, persistence and 
directionality were analyzed. Persistence is defined as the time a cell moves in 
a given direction. If an object is not turning, its persistence is the same as the 
speed. Directionality is similar to persistence, but given in degrees, where 1 
represents a straight path, smaller value stand for a meandering path. 
Untransfected B16F1 cells traveled with an average speed of 1.78 ± 0.54 
µm/min, with high persistence and directionality close to 1 (Figure 3.17). In 
comparison, cells expressing GAR22β only had an average speed of 0.56 ± 0.23 
µm/min, really low persistence and an average directionality below 0.5 (Figure 
3.17). Images of cells expressing GAR22β showed that these cells often did not 
form the distinct lamellipodia as seen in untransfected cells, but rather 
formed various smaller lamellipodia (Figure 3.16). Cells expressing GAR22α 
moved with an average speed of 1.5 ± 0.8 µm/min, which is comparable to the 
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speed of untransfected cells or GFP control cells. However, these cells showed 
a very low persistence and directionality below 0.5 like cells expressing 
GAR22β (Figure 3.17). Albeit, by observing the cells, there was no visible 
alteration in the formation of a distinct lamellipodium (Figure 3.16). Taken 
together, the overexpression of GAR22β impairs directional cell motility. 
 
 
Figure 3.16: GAR22β  impairs directional cell motility of B16F1 cells 
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B16F1 cells were transiently transfected with GAR22-GFP fusion constructs, plated on laminin 
and observed by time-lapse microscopy. Arrowheads point to lamellipodial structures. Inserts 
in the upper row showing GFP expression of analyzed cell. Scale bar represents 40 µm and 
indicated time (t) is in minutes. 
 
 
 
Figure 3.17: GAR22β  influences directionality and persistence of B16F1 cells 
B16F1 cells were transiently transfected with GAR22-GFP fusion constructs and observed by 
time-lapse microscopy as in Figure 3.16. Single cells were analyzed for various parameter 
including average speed, persistence and directionality. Box and whiskers plot: the line in the 
middle of the box indicates the median; the top of the box indicates the 75th percentile, 
whereas the bottom of the box indicates the 25th percentile. Whiskers represent the 10th 
(lower) and 90th (upper) percentile, respectively. Asterisks indicate p-value (*) p=0.005; (**) 
p<0.0001. 
 
RESULTS         69 
 
3.7 GAR22 interacts directly with EB1 in vitro 
Since little is known about GAR22, the identification of potential binding 
partners is of importance and can contribute to a better understanding of the 
molecular function of this protein. Therefore, tandem affinity purification 
(TAP) was chosen to screen for interaction partners. TAP coupled to mass 
spectrometry is an unbiased method to identify proteins that purify with the 
bait protein (Hayden and Ghosh, 2004). Several of the purified fragments 
were identified as deletions of GAR22 as well as heat shock proteins, which 
were considered as contamination. One of the bands was identified as 
complement component 1 (Q subcomponent binding protein, mitochondrial 
precursor), whereas another band was identified as microtubule associated 
protein RP/EB family member 1 (APC-binding protein EB1) (Figure 3.18A). 
The TAP assay was performed with GAR22β and GAR22C, which both 
pulled down EB1. To confirm the result of the mass spectrometry, purified 
proteins were subjected to in vitro binding assay (Figure 3.18B). It was 
possible to pull down EB1 with GAR22β and GAR22C, but not with 
GAR22α (Figure 3.18B and C).  
To identify a possible binding site of EB1 within the GAR22 sequence, 
different deletion mutants were generated. Since the binding site was expected 
to be within the carboxy-terminal region, the deletion mutants were generated 
by reducing progressively the carboxy-terminus (Figure 3.19). The purified 
proteins were subjected to in vitro binding assay. All deletions mutants, 
except GAR22Δ371 were still able to bind EB1. By calculating the binding 
ratio of GAR22 to EB1, it was shown that GAR22Δ399 was able to bind EB1 
as strong as GAR22β (Figure 3.18B and C). Therefore, it is likely that the 
binding site for EB1 is located between amino acid 371 and 399 of GAR22β 
(Figure 3.19).  
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Figure 3.18: EB1 is a binding partner of GAR22 
Tandem affinity purification (TAP) of GAR22β or GAR22C containing cell lysates following 
mass spectrometry identified EB1 as binding partner of GAR22β and GAR22C. (A) 
Coomassie staining of SDS gel with TAP elute (numbers are different identified bands). 
Control was NTAP-tag alone. (B) Binding was also confirmed by in vitro binding assay with 
purified protein following Western blotting. Coomassie staining shows protein mass of 1µl of 
each protein fraction used in the in vitro pull down assay. Asteriks indicate the band used for 
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calculating binding ratio (C) Binding ratio of input GAR22 protein to recovered EB1 protein 
after in vitro binding assay. 
 
 
Figure 3.19: Schematic representation of GAR22 deletion mutants 
Various deletion mutants were generated to identify the EB1 binding site in GAR22. Orange 
sequences are GAR22α and GAR22β; blue sequences are deletion mutants terminated at the 
indicated amino acid. Its binding to EB1 is indicated as shown in Figure 3.18. 
 
3.8 EB1-GAR22 interaction in vivo 
To demonstrate that EB1 and GAR22 also interact in vivo, an inducible 
expression system was used (2.4.1). The expression of GAR22β, GAR22C or 
GFP-control in HeLa-tet was induced by doxycycline. Cell lysates containing 
GAR22-GFP or GFP alone were subjected to immunoprecipitation (2.14) 
using an antibody against GFP to specifically pull down ectopic GAR22. EB1 
was identified in the precipitate of GAR22β and GAR22C containing lysates 
by Western blotting (Figure 3.20). In control cells EB1 was not precipitated. 
It has been known that EB1 binds to the plus ends of microtubules and 
GAR22 has been shown to interact with microfilaments and microtubules 
(Goriounov et al., 2003; Juwana et al., 1999). Therefore, it cannot be excluded 
that the binding of EB1 and GAR22 is partly mediated by these cytoskeletal 
structures. To test this possibility, HeLa-tet cells were treated with 
nocodazole to disassemble microtubules (Figure 3.20A) and then subjected to 
immunoprecipitation. The disassembly of microtubules did not inhibit the 
binding of EB1 to GAR22β or GAR22C. Next, it was tested, whether the 
binding of GAR22 to actin has an influence on binding to EB1. To that end, 
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cells were treated with latrunculin to disassemble filamentous actin and 
subjected to immunoprecipitation (Figure 3.20B). It was found that 
microfilaments were not necessary to promote the binding of EB1 with 
GAR22β or GAR22C. Taken together, the binding of EB1 to GAR22 does not 
depend on the association of GAR22 to actin or microtubules.   
 
 
Figure 3.20: EB1 binds GAR22β  and GAR22C in vivo 
An inducible system of HeLa-tet cells were stably transfected with GAR22-GFP variants. Cells 
were induced to express GAR22 with doxycycline or left untreated and (A) treated with or 
without nocodazole to disassemble microtubules and (B) with or without latrunculin to 
disassemble cytofilaments. Lysates were prepared and subjected to immunopreciptation 
using GFP antibody following Western blotting. 
 
To determine whether GAR22 and EB1 co-localize to discrete sub-cellular 
structures, NIH3T3 cells stably transfected with different GAR22-GFP 
variants were subjected to immunofluorescence staining. In untransfected 
NIH3T3 cells EB1 formed a comet like tail located at the plus ends of 
microtubules (Figure 3.21, Figure 3.22). The microtubule structure displayed 
a radial form and the microtubule plus ends pointed towards the cell cortex. 
Cells expressing GAR22α showed a similar comet-like shape of the EB1 
staining and regular microtubule structures, whereas cells expressing GAR22β 
did not show the regular shape for EB1 seen in control cells, but rather a 
displacement to the side of GAR22β. It is also notable that cells expressing 
GAR22β exhibited collapsed microtubule structures. Although GAR22C was 
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able to bind to EB1 in vivo and in vitro, GAR22C had no impact on the 
location of EB1 within the cell (Figure 3.21, Figure 3.22).  
 
 
Figure 3.21: GAR22β  displaces EB1 from the microtubule plus ends causing a collapse 
of microtubule cytoskeleton 
NIH3T3 cells stably transfected with GAR22-GFP fusion constructs were fixed and stained for 
EB1 and tubulin. Scale bars represent 10 µm. 
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Figure 3.22: Displacement of EB1 by GAR22β  from the microtubule plus ends causes 
collapsed microtubule cytoskeleton 
NIH3T3 cells stably transfected with GAR22-GFP fusion constructs were fixed and stained for 
EB1 and tubulin. Here, overlays from Figure 3.21 are shown. White boxes in the right upper 
corner of each pictures presents an enlargement of the indicated side in the respective 
picture. Arrowheads point to EB1 staining and respective sides in tubulin staining.  
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3.9 EB1-GAR22 binding depends on phosphorylation of GAR22 
GAR22 is phosphorylated in serum-starved fibroblasts mainly on 
Serine/Threonine residues (Goriounov et al., 2003). It contains five putative 
consensus sequences for cdks. To address the role of phosphorylation in 
GAR22 function, Serine and Threonine in these sequences where mutated to 
Alanine to mimic the non-phosphorylated form. Figure 3.23 indicates the 
amino acid, which were mutated. 
  
 
Figure 3.23: Schematic representation of GAR22 
The scheme shows a representation of the GAR22 protein with calponin homologue (CH) 
domain and GAR domain in green boxes as well as potential phosphorylation sites. The 
numbers indicate the amino acid position in human GAR22β protein. 
 
To investigate whether the binding of EB1 to GAR22 depends on 
phosphorylation, phosphatase treatment of immunoprecipitated samples was 
performed. To exclude any impact of the potential phosphorylation of EB1, 
the phosphatase-treated precipitate was one more time incubated with cell 
lysate containing unmodified EB1 (Figure 3.24). From control lysates lacking 
GAR22, EB1 could not be precipitated. Conversely, in lysates containing 
GAR22β or GAR22C, EB1 co-precipitated with GAR22. Phosphatase 
treatment significantly reduced the binding to EB1 to GAR22β, but not to 
GAR22C (Figure 3.24A and C).  
Next, a GAR22 mutant, in which all five putative cdk sites were mutated to 
Alanine, and the double mutant T334A and S394A (Figure 3.23) were used in 
a similar assay. Both mutated forms of GAR22 were less efficient in binding 
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to EB1. Moreover, phosphatase treatment further impaired the association of 
GAR22 with EB1 indicating that additional phosphorylation sites are 
involved in this process (Figure 3.24B and C).  
Indeed, preliminary phospho-specific mass spectrometry analysis indicated 
that GAR22 is phosphorylated at multiple sites (Table 3.2). Using Net Phos 
Kinase program (http://www.cbs.dtu.dk/services/NetPhosK) it was possible 
to identify potential kinases such as cdk5 and GSK3β that are also involved in 
cytoskeleton remodeling in various cellular systems. 
 
 
Figure 3.24: EB1-GAR22 binding is dependent on phosphorylation 
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An inducible system in HeLa cells was used to express various GAR22-GFP constructs 
dependent on doxycycline. Cells were lysed and subjected to immunoprecipitation followed by 
a phosphatase treatment; eluted proteins were subjected to SDS-PAGE and Western blotting. 
(B) NIH3T3 cells transiently expressing GAR22β-GFP or GAR22 with mutated potential 
phosphorylation site were lysed and subjected to immunoprecipitation including a 
phosphatase treatment. (C) Binding affinity ratio was calculated from GAR22 and EB1 
precipitates, left side respective to (A), right side respective to (B).  
 
Table 3.2: Identified phosphorylation sites with respective putative kinases 
Site identified by mass spectrometry Possible kinase by NetPhos 1.0 
S11 PKC 
S327 CKI, PKC, PKG 
T328 not identified 
T334 (*) p38MAPK, cdk5, GSK3β 
S403 DNAPK 
S405 RSK, PKA 
S436 RSK, DNAPK, PKA  
S438 RSK, PKB (Akt1), PKA 
S479 cdk5, GSK3β 
S486 PKA 
 
Phosphorylation sites were identified by mass spectrometry and respective putative kinases 
were identified using NetPhosK 1.0 (http://www.cbs.dtu.dk/services/NetPhosK/) with a 
threshold of 0.5. Asterisk: site was already identified as putative cdk site and mutated. 
 
3.10 GAR22β impairs reassembly of microtubule cytoskeleton 
As reported above, the overexpression of GAR22β resulted in the alteration of 
microtubule architecture presumably through binding to EB1 and the collapse 
and bundling of microtubules (Figure 3.21). Therefore, it was of interest to 
test the influence of GAR22 on the reassembly of microtubule cytoskeleton. 
For that, cells expressing GAR22 variants or control cells were treated with 
nocodazole to disassemble microtubules (2.12). After the removal of 
nocodazole, cells immediately started to recover their microtubule structure. 
The cells were fixed after various periods of time and analyzed for the 
reassembly of microtubules.  
Untransfected cells or cells expressing either GFP or GAR22α already started 
to reassemble microtubules after 3 min. In some cells fully recovered 
microtubule structures were seen already after 5 min. After 10 min, more 
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than 50% of the cells recovered the normal microtubule structure (Figure 
3.25).  
 
 
Figure 3.25: GAR22β  impairs the reformation of microtubule cytoskeleton 
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Stably transfected NIH3T3 cells were treated with nocodazole for 1 hour, after nocodazole 
removal, cells were recovering for various time points (0, 3, 5, 7.5, 10, 30 min) and fixed. (A) 
Representative pictures of tubulin stained NIH3T3 cells of time point 5, 10 and 30 min. Scale 
bar represents 5 µm. (B) Analysis of microtubule recovery. Cells were analyzed by judging 
reassembly of the microtubule cytoskeleton by microscopy. Cells were counted as positive 
when the microtubules were fully recovered. At least 100 cells per time point and treatment 
were counted.  
 
In contrast, in cells expressing GAR22β the reassembly of the microtubules 
appeared to be much slower. Ten minutes after nocodazole removal, only a 
few cells (less then 10%) have regained full microtubule structures. At this 
time point, most of the cells just began to recover the microtubule structures. 
After 30 min, almost all cells analyzed showed fully recovered microtubule 
cytoskeletons (Figure 3.25). Therefore, it was concluded that GAR22β 
expression delays microtubule reassembly. 
3.11 Contribution of CH and GAR domains to GAR22 function 
It has been shown that GAR22 comprises of CH domain acting as an actin 
binding domain and GAR domain, described as microtubule binding domain 
(Goriounov et al., 2003). To elucidate the contribution of the two domains to 
GAR22 function deletion mutants lacking either CH or GAR domain were 
generated by overlap-extension PCR (2.3.2, Figure 3.26). The resulting 
products were cloned as GFP fusion proteins and expressed in B16F1 and 
NIH3T3 cells. As for the other GAR22 variants, their effect on cell motility 
and cytoskeleton architecture was analyzed by immunofluorescence staining 
and wound healing assay. 
 
 
Figure 3.26: Schematic representation of GAR22 deletion mutants 
Schematic representation of GAR22 deletion mutants GAR22ΔCH (561 amino acids) and 
GAR22ΔGAR (609 amino acids).  
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First, localization of GAR22ΔCH and GAR22ΔGAR was visualized in B16F1 
cells. For that, B16F1 cells were transiently transfected with the GAR22-GFP 
constructs, plated on laminin, fixed and stained for actin (Figure 3.27). As 
expected in cells expressing GAR22 lacking the CH domain (GAR22ΔCH), 
there was no co-localization with actin anymore. Moreover, the staining 
showed bundle-like structures, which reached far into the lamellipodia (Figure 
3.27, upper row). On the other hand, GAR22ΔGAR still co-localized very well 
with the actin cytoskeleton. Interestingly, the localization was restricted only 
to filamentous actin in the cell body. GAR22ΔGAR was absent in 
lamellipodia, where high actin turn over takes place (Figure 3.27, lower row).   
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Figure 3.27: Localization of GARΔCH and GAR22ΔGAR in B16F1 cells 
B16F1 cells were transiently transfected GARΔCH and GAR22ΔGAR GFP fusion constructs, 
plated on laminin, fixed and stained for actin with fluorescent-labeled phalloidin. White boxes 
indicate the region of enlarged structures in the respective upper row; scale bars represent 10 
µm and arrowheads point to structures typically for the individual deletion mutants of GAR22.  
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To further investigate these findings, NIH3T3 cells were stably transfected 
with GAR22ΔCH and GAR22ΔGAR as described before and stained for actin, 
tubulin and EB1 (Figure 3.28, Figure 3.29). GAR22ΔCH did not co-localize 
with actin filaments in NIH3T3 cells and bundle-like structure were detected, 
which reached into the periphery of the cell (Figure 3.28A). GAR22ΔCH and 
EB1 almost perfectly localized at the bundle-like structures. In cells expressing 
GAR22ΔCH, EB1 was displaced to a greater extent than in cells expressing 
GAR22β. Thick bundles of GAR22ΔCH and EB1 co-localized with 
microtubule structures that again showed a collapsed architecture (Figure 
3.28B). Conversely, the localization of GAR22ΔGAR in NIH3T3 cells was 
restricted to filamentous actin in the cell body and was not able to reach 
protrusional structures in the cell (Figure 3.29A). GAR22ΔGAR co-localized 
to actin stress fibers. In cells expressing GAR22ΔGAR the microtubules 
structures had a more radial architecture and the EB1 displayed its comet-like 
shape at the plus ends of microtubules. Only some of EB1 was localized to 
structures, where GAR22ΔGAR was found (Figure 3.29B). In summary, 
GAR22ΔCH co-localizes strongly with microtubules and dominantly displaces 
EB1, whereas GAR22ΔGAR co-localizes with an actin structure known as 
stress fibers and failed to displace EB1.  
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Figure 3.28: Sub-cellular distribution of GAR22ΔCH and its activity on EB1 localization 
and microtubule architecture  
NIH3T3 cells were stably transfected with GAR22ΔCH and subjected to immunofluorescence 
staining. (A) Cells were stained for actin with fluorescent-labeled phalloidin. Arrowhead points 
to GAR22ΔCH structure reaching in a protrusion. (B) Cells were stained for tubulin and EB1. 
White boxes contain enlarged part of the respective image. Scale bars represent 10 µm and 
arrowheads point to structures of EB1 GAR22ΔCH co-localization with respect to microtubule 
staining.  
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Figure 3.29: GAR22ΔGAR sub-cellular distribution and its activity on EB1 localization 
and microtubule architecture 
NIH3T3 cells were stably transfected with GAR22ΔGAR and subjected to 
immunofluorescence staining. (A) Cells were stained for actin with fluorescent-labeled 
phalloidin. Arrowhead points to GAR22ΔGAR structure and stress fibers. (B) Cells were 
stained for tubulin and EB1. White boxes contain enlarged part of the respective image. Scale 
bars represent 10 µm and arrowheads point to EB1 localization in the cell expressing 
GAR22ΔGAR.  
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The next step was to assess the influence of GAR22ΔCH and GAR22ΔGAR 
on cell migration. For that, wound healing assays were performed as described 
before. Again, one part of the wound had untransfected cells and the other 
one transfected cells as indicated by the GFP expression (Figure 3.30, top 
row). By comparing the cell movement of transfected cells to untransfected 
cells it was difficult to see a difference. Cells expressing GAR22ΔGAR were 
likewise spindle shaped and motile as control cells. In contrast, cells expressing 
GAR22ΔCH had a rounder morphology and therefore seemed slower in cell 
movement. Despite the difference in morphology and speed, statistical analysis 
revealed that both constructs slightly but significantly inhibited cell 
migration, although not to the same extend as cells expressing full-length 
GAR22β (Figure 3.31).  
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Figure 3.30: GAR22ΔCH and GAR22ΔGAR and its influence on cell motility 
NIH3T3 cells were stably transfected with GAR22ΔCH and GAR22ΔGAR and subjected to 
wound healing assay. One side of the wound had untransfected cells (wild type; WT) and the 
other one transfected cells as indicated by GFP expression. Time (t) is indicated in hours. 
Scale bars represent 100 µm and arrows at the bottom indicate the approximate distance the 
cells have traveled.  
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Figure 3.31: GAR22ΔCH and GAR22ΔGAR reduces impaired cell motility of GAR22β  
expressing cells 
NIH3T3 cells were stably transfected with GAR22-GFP fusion constructs and subjected to 
wound healing assay using cell culture inserts. Statistical analysis of wound closing was done 
as follows, pictures of the same area of the wound were taken at the beginning and after 16 
hours and distance was measured with Graphic Converter software. Box and whiskers plot: 
the line in the middle of the box indicates the median; the top of the box indicates the 75th 
percentile, whereas the bottom of the box indicates the 25th percentile. Whiskers represent the 
10th (lower) and 90th (upper) percentile, respectively. Asterisks indicate p-value <0.0001. 
 
Although the deletion of the CH and GAR domain showed a very pronounced 
and very distinct localization in the cell, the impact on cell migration was not 
as strong as GAR22β. GAR22ΔCH reinforces the ability to microtubule 
bundles and EB1 displacement, whereas GAR22ΔGAR sub-cellular localization 
is to more stable actin structures such as stress fibers. In summary, these 
data indicated that the CH and GAR domain are required for the potential 
role of GAR22 in the regulation of cell motility.  
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4 Discussion 
4.1 Impact of GAR22 on erythropoiesis 
This study aimed to analyze the impact of thyroid hormone receptor (TR) on 
growth and differentiation of erythroid progenitors and to identify TR target 
genes. It was demonstrated that SCF/Epo progenitors express TRα, RARα, 
RXRα and RXRβ, and that addition of thyroid hormone (T3) and 9-cis-
retinoic acid (9cRA) accelerates red cell differentiation concomitant with the 
induction of growth arrest. T3 had a more pronounced effect than 9cRA, and 
the combination of both showed even more enhanced activity. Thyroid 
hormone T3 and its precursor thyroxine (T4) have been known to be 
implicated in erythropoiesis for many years. For instance, patients with 
hypothyroidism frequently suffer from anemia (Fein and Rivlin, 1975). 
Similarly, in mice, inherited primary hypothyroidism causes anemia (Beamer 
et al., 1981). Additionally, the oncogenic TR version v-erbA contributes to 
fatal erythroleukemia in birds (Beug et al., 1994) and v-erbA was found to 
block red cell differentiation in vitro (Disela et al., 1991; Schroeder et al., 1992; 
Zenke et al., 1988; Zenke et al., 1990).  
Stress erythropoiesis initiated by hypoxia, blood loss or erythroleukemia are 
conditions where the body reacts with increased erythropoiesis, which is 
mediated by elevated Epo and SCF levels, and the release of glucocorticoids 
(Bauer et al., 1999; Bozzini et al., 1994; Ganguli et al., 2002; Socolovsky, 2007). 
TRα knock out mice show altered stress erythropoiesis response (Kendrick et 
al., 2008). Additionally, in another mouse model it was demonstrated that 
glucocorticoid receptor plays a role in stress-induced erythropoiesis in adult 
anemic mice (Bauer et al., 1999; Kendrick et al., 2008). Overall, these studies 
support the notion that TR plays a major role in the events leading to red 
blood cell development under stress conditions.  
4.1.1 Differentiation of erythroid progenitors in response to T3 
In this work, I showed that the expression of Band 3 increased following T3 
or T3+9cRA treatment. Band 3 is an anion exchanger of the membrane of 
red blood cells that anchors erythroid cytoskeleton to the membrane. A 
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previous study showed that v-erbA, the oncogenic version of TR, blocks 
erythroid differentiation by inhibiting Band 3 expression in chicken (Zenke et 
al., 1988). Therefore, increased Band 3 expression by ligand-activated TR 
might consequently promote accelerated erythroid differentiation.  
Furthermore, SCF/Epo cells treated with TR ligands drastically decreased E-
cadherin expression, whereas untreated cells virtually did not change the 
expression of E-cadherin. However, it is not clear whether ligand-activated TR 
regulates the expression of E-cadherin directly or indirectly. E-cadherin 
belongs to a group of highly conserved transmembrane glycoproteins that are 
involved in cell-cell interaction and adhesion (Geiger and Ayalon, 1992; 
Grunwald, 1993). The expression of E-cadherin in hematopoietic cells is 
restricted to defined maturation stages of erythroid lineages (Armeanu et al., 
1995; Buhring et al., 1996). It has been shown that erythroblasts and 
normoblasts express E-cadherin, whereas fully differentiated red cells do not 
(Armeanu et al., 1995). In vivo, erythroblasts proliferate, differentiate and 
enucleate within erythroblastic islands, where cell-cell interaction and cell-
matrix interaction are of utmost importance for normal and efficient 
differentiation (Chasis and Mohandas, 2008). One of the adhesion molecules 
that is crucial for this process is E-cadherin, demonstrated by blockage of 
erythroblasts differentiation using inhibitory anti-E-cadherin antibodies 
(Armeanu et al., 1995). The drastic reduction in E-cadherin levels correlates 
with the accelerated differentiation induced by T3 treatment. 
GATA-2 and c-kit were also downregulated during red cell differentiation and 
this downregulation was enhanced by T3. C-kit, the receptor of SCF, 
promotes cell cycle progression resulting in proliferation (Munugalavadla et 
al., 2005). GATA-2 is expressed in multipotent cells, where it regulates gene 
expression following the formation of a complex with LMO2 and SCL/tal1. 
At a more committed stage of differentiation GATA-2 will be replaced by 
GATA-1, a more erythroid-restricted factor (Anguita et al., 2004). Thus, 
ligand-activated TR likely mediates accelerated differentiation by inhibiting 
proliferation signals and concomitantly enhancing erythroid commitment. 
GATA-1 represents another key regulator of red cell development (De Maria 
et al., 1999; Leonard et al., 1993; Ribeil et al., 2007). However, GATA-1 and 
its targets EKLF and ALAD (Rylski et al., 2003) were not affected by T3 
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treatment. Given the observation that T3 effectively accelerates red cell 
differentiation, two potential molecular mechanism can be envisaged: (i) T3 
may cause an accelerated up- or downregulation of genes normally involved in 
red cell differentiation, like globin, heme biosynthesis enzymes, cell cycle 
regulators, cytoskeleton remodeling factors, etc or (ii) T3 may induce the 
expression of distinct sets of genes, which lead to accelerated differentiation 
and growth inhibition by an additional or alternative program. To investigate 
these possibilities gene expression profiling was employed to identify 
downstream targets of TR. Hierarchical cluster analysis of the DNA 
microarray data revealed specific changes in gene expression during 
differentiation, which were accelerated by hormone treatment. Further data 
mining identified a cluster of genes, which were highly induced by hormone 
treatment. This gene cluster included BTEB1, a known TR target gene 
identified in neural cells (Denver et al., 1999) and GAR22, a novel TR target 
gene, which so far has not been implicated in erythropoiesis.  
BTEB1 and GAR22 are not induced during normal red cell development and 
thus may represent components of alternative signaling pathways with a 
potential function in accelerating erythropoiesis. However, expression of Band 
3, E-cadherin, GATA-2 and c-kit, which are normally involved in 
erythropoiesis, were influenced by T3, indicating an accelerated program of 
regular erythropoiesis. Thus, it is possible that T3-driven differentiation 
results in both the modulation of genes normally involved in erythropoiesis 
and genes that belong exclusively to an alternative program.  
4.1.2 A novel TR target gene: GAR22 
As mentioned above, one of the T3 induced genes, GAR22, was so far not 
known as a TR target gene. GAR22 was initially identified during a genetic 
screen for potential tumor suppressor genes on human chromosome 22 
(Zucman-Rossi et al., 1996) and exhibits extensive homology to the growth 
arrest specific 2 (Gas2) gene (Goriounov et al., 2003; Schneider et al., 1988). 
Due to this homology, it was termed Gas2-related gene on chromosome 22 
(also referred to as Gas2-like 1, GAS2L1). In addition, GAR22 has the ability 
to interact with actin and microtubule cytoskeletons (Goriounov et al., 2003). 
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T3 induced GAR22 expression and growth inhibition, suggesting that GAR22 
may be involved in causing growth arrest. Cell cycle withdrawal represents an 
important step in terminal red cell differentiation. Hence, GAR22 may be a 
component contributing to this process, as suggested by the observation that 
ectopic GAR22 expression in SCF/Epo cells caused delayed cell cycle 
progression, and enhanced downregulation of GATA-2 and c-kit.  
Microtubule dynamics play a fundamental role in cell division. Increased 
microtubule dynamics at the onset of mitosis promote alignment of 
chromosomes in metaphase. In anaphase, microtubule dynamics contribute to 
the generation of forces that segregate chromosomes and elongate the mitotic 
spindle (Scholey et al., 2003). EB1, a novel binding partner of GAR22, as 
discussed below, is a plus end binding protein that regulates microtubule 
behavior during mitosis and cytokinesis. It has been shown in Xenopus 
oocytes that downregulation of EB1 or p150glued during anaphase leads to the 
alteration of astral microtubule elongation toward the cell cortex resulting in 
prolonged cytokinesis and suppression of cleavage furrow initiation 
(Strickland et al., 2005). However, downregulation of EB1 did not lead to 
mitotic arrest. In Schizosaccharomyces pombe the EB1 homologue Mal3 is not 
essential for cell division, although cells lacking Mal3 exhibit mitotic defects 
with elevated levels of chromosome instability and prolonged mitosis 
(Asakawa and Toda, 2006). Moreover, inhibition of EB1 or APC causes 
defects in chromosome alignment, but no mitotic arrest (Green et al., 2005). 
As the actin cytoskeleton is required for the formation of the contractile ring 
within the cleavage furrow, it is possible that GAR22 may contribute to cell 
cycle progression by regulating microtubule and microfilament behavior.  
Red blood cells travel through very small capillaries. This is made possible by 
their unique cytoskeleton, which is highly deformable and stable. To achieve 
this, terminal red blood cell differentiation is characterized by intense 
cytoskeletal remodeling. In addition, cytoskeletal components are important 
for extrusion of the nucleus, which is promoted by microtubules (Chasis et 
al., 1989) and the formation of a contractile ring composed of microfilaments 
(Ji et al., 2008). Given the ability of GAR22 to associate with actin filaments 
and microtubules, it is possible that it plays a role in these processes. 
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4.2 Characterization of GAR22 function on cell migration 
Next, the molecular function of GAR22 on cytoskeletal structures was studied 
using motile cell systems. First, it was found that not only the localization, 
but also the dynamics of GAR22 mirrors that of actin cytoskeleton in both 
B16F1 and NIH3T3 cells. In these cellular systems the overexpression of 
GAR22β severely decreased both speed and persistence in movement. As for 
the inhibitory effect of GAR22α, cells decreased in persistence, but not so 
much in speed.  
In a search for interaction partners of GAR22, EB1 was identified by tandem 
affinity purification. Overexpression of GAR22β revealed profound 
displacement of EB1 and also caused the microtubules to collapse. An EB1 
binding site was found within the carboxy-terminus of GAR22β, proposing a 
new function for this part of GAR22. GAR22α, which is a splice variant, 
cannot bind EB1, therefore it may be suggested that the regulation of the 
splice event might be a tool for the cells to adjust the expression of GAR22β 
protein and therefore counteract the function of GAR22β. The potential EB1 
binding site between amino acid 371 and 399 of GAR22 contains negatively 
charged amino acids. EB1 protein sequence consists of an acidic tail (positively 
charged last 18 amino acids), which can bind to p150glued and CLIP170 
(Askham et al., 2002; Komarova et al., 2005). Thus, it is likely that the 
interaction of GAR22 with EB1 occurs via the acidic tail of EB1. Other EB1 
binding proteins might be affected by the displacement of EB1 in GAR22β 
expressing cells, thereby affecting motility in these cells. Consistent with the 
effect on EB1, microtubule reassembly was impaired in GAR22 expressing cells 
indicating that GAR22 has an influence on microtubule architecture. 
Additionally, the binding of EB1 to GAR22 is regulated by the 
phosphorylation of GAR22 by so far unknown kinases.  
The impact of actin binding and microtubule binding domain was also 
explored. The effect of deletion mutants, which lack either the CH 
(GAR22ΔCH) or the GAR (GAR22ΔGAR) domain, on cell migration was less 
prominent than that of GAR22β. Cells expressing GAR22ΔCH showed 
bundled microtubules with massive targeting of EB1 to those structures. Here 
GAR22ΔCH and EB1 showed a very robust co-localization, whereas 
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GAR22ΔGAR did not. GAR22ΔGAR was mainly found to localize to the more 
stable part of the actin cytoskeleton, the stress fibers. The potential EB1 
binding site between amino acid 371 and 399 was not modified in GAR22ΔCH 
or GAR22ΔGAR indicating an additional regulation of EB1 binding possibly 
followed by conformational change of GAR22. It is also possible that the lack 
of one of these domains results in a different structure of GAR22 influencing 
the binding to EB1. 
4.2.1 EB1 as interacting partner of GAR22 
EB1 is a well-studied protein and interacts with APC, a tumor suppressor 
protein (Morrison et al., 1998; Su et al., 1995). EB1 belongs to the group of 
+TIP proteins. It is found at the plus ends of microtubules also during 
mitosis (Morrison et al., 1998). EB1 is one of three proteins of the end-
binding protein family. It is ubiquitously expressed and promotes microtubule 
polymerization by increasing the frequencies of rescue and suppressing 
catastrophe events on microtubules (Komarova et al., 2009). The amino-
terminus contains a single CH domain, which was identified here as a 
microtubule-binding domain (Bu and Su, 2003; Hayashi and Ikura, 2003). 
Dimerization of EB1 promotes microtubule growth in vitro and plus end 
tracking activity in vivo (Slep and Vale, 2007). The carboxy-terminus consists 
of a unique motif only found in the EB family (Bu and Su, 2003). EB1 is able 
to interact with almost all other +TIPs via its carboxy-terminal domain 
(Berrueta et al., 1999; Bu and Su, 2003; Komarova et al., 2005; Mimori-
Kiyosue et al., 2005; Su et al., 1995). EB1 can bind to microtubule plus ends 
even in the absence of APC, CLASPs, CLIPs, p150glued and spectraplakins 
(Hayashi and Ikura, 2003). The interaction with other +TIPs is not necessary 
for EB1 tip tracking, but it releases the auto-inhibitory conformation of EB1 
(Morrison, 2007).  
EB1 plays an important role in microtubule stability. Displacement of EB1 by 
GAR22β leads to altered microtubule architecture, which would explain the 
non-directional migration of cells overexpressing GAR22β. Additionally, a 
delayed microtubule reassembly in cells expressing GAR22β was observed. It 
has been reported that depletion of EB1 reduces microtubule minus-end 
anchoring at centrosomes and delays microtubule regrowth from centrosomes 
94  DISCUSSION 
 
 
(Louie et al., 2004). Therefore GAR22β may negatively regulate EB1 during 
new assembly of microtubules at the centrosomes. The influence on 
microtubule dynamics and stability still has to be explored. But it can be 
speculated that GAR22 can influence microtubule dynamics by regulating 
EB1 binding to plus ends of microtubules.  
4.2.2 Influence of GAR22 on cell migration 
Cells expressing GAR22β showed significantly reduced speed in their 
migration. Speed of a cell depends on adhesiveness to the substratum 
determined by the number and affinity of focal adhesions. Microtubules in 
contact with focal adhesions induce destabilization and disassembly of them, 
which is mediated by dynamin and FAK (Ezratty et al., 2005; Kaverina et al., 
1998). If GAR22 takes part in regulating microtubule stability via EB1, it 
might thereby influence focal adhesion stability. Hence, migration speed and 
directional movement may be controlled. Therefore, it is of value to elucidate 
the influence of GAR22 on focal adhesion stability. 
Establishing polarity is a necessary requirement for directed cell migration. 
Polarity is defined by asymmetric distribution of proteins and cytoskeletal 
structures as well as the reorientation of Golgi and MTOC. It is regulated by 
Par complex and small RhoGTPases, which in turn control microtubule and 
actin dynamics. Actin dynamics drives motility by lamellipodia and filopodia 
protrusion, whereas microtubules sustain directionality of a migrating cell. It 
would be interesting to explore whether small RhoGTPases influence or be 
influenced by GAR22.  
4.2.3 GAR22 at the interplay of microfilaments and microtubules 
Small RhoGTPases are part of a regulatory interaction at the interplay 
between microfilaments and microtubules. On the other hand, proteins that 
are able to bind both cytoskeletal structures could regulate the interplay in a 
structural manner (Rodriguez et al., 2003). For example, spectraplakins, a 
group of actin-microtubule-crosslinkers, encode for tandem repeats of CH 
(calponin homologue) domain, which function as actin binding domain (Roper 
et al., 2002) and microtubule binding domain. The CH domain, first identified 
in the regulatory protein Vav, was described as an actin-binding domain in a 
variety of proteins associating with F-actin (Castresana and Saraste, 1995). 
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Although, the ability of a single CH domain binding to actin is still a matter 
of debate (Gimona et al., 2002; Gimona and Mital, 1998), the binding of 
GAR22 to actin is clearly mediated by its single CH domain. 
The second functional domain in GAR22 is Gas2/GAR domain. Originally 
identified in Gas2 (growth arrest-specific gene 2), it was recognized as 
microtubule binding domain in MACF (Sun et al., 2001). The GAR domain 
in MACF is homologue to Gas2 and GAR22 regions (Sun et al., 2001). So far 
there are four proteins in mammalians that contain a GAR domain, MACF 
(ACF7), MACF2, Gas2 and GAR22. Homologues to MACF in Drosophila 
(kakapo/shortstop) and Caenorhabditis elegans exist (Sun et al., 2001). Gas2 
shares the highest homology with GAR22, which tempts to speculate about 
functional overlapping. Gas2 was first characterized as G0-specific gene, which 
is negatively regulated by growth induction (Schneider et al., 1988). Also 
GAR22 was shown to be upregulated in serum-starved cells (Goriounov et al., 
2003). These cells have reduced metabolism and motility, as well as inactive 
small RhoGTPases. Therefore, endogenous GAR22 could negatively regulate 
microtubule dynamics and polarity by displacing EB1 from plus-end tips of 
microtubules in immobilized cells. Based on the binding capability of GAR22 
to filamentous actin, microtubules and EB1, GAR22 could be part of 
regulatory and structural interactions.  
4.2.4 Phosphorylation of GAR22 and its potential function 
It was previously demonstrated that GAR22 is phosphorylated on 
Serine/Threonine residues (Goriounov et al., 2003). One potential candidate is 
cdk5, for which I identified two specific phosphorylation sites in GAR22. 
When one of the identified sites (S334) was mutated, the binding affinity of 
EB1 to GAR22 was decreased, but it was not sufficient to abolish binding, 
indicating that additional phosphorylation sites are implicated.  
Cdk5, although showing homologies with cdk2, has no regulatory function of 
cell cycle progression. Cdk5 is regulated by the non-cyclin proteins p35, p39 
and p25 (Xie and Tsai, 2004). Initially, cdk5 expression was detected in the 
nervous system, but many other non-neuronal tissues with cdk5 expression 
have been identified (Dhavan and Tsai, 2001). Its expression is critical for the 
migration of post-mitotic neurons, because a lack of cdk5 or its activator lead 
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to severe neuronal positioning defects in the developing brain and 
consequently to perinatal lethality in knockout mice (Xie and Tsai, 2004). 
Many of the known cdk5 substrates are directly implicated in actin and 
microtubule dynamics (Xie and Tsai, 2004). Additionally, GAR22 is highly 
expressed in the brain (Goriounov et al., 2003) and my preliminary 
experiments showed a reduced axon growth in neurons when GAR22β was 
overexpressed (in collaboration with B. Knöll, Interfaculty Institute for Cell 
Biology, Eberhard Karl University, Tübingen, Germany). Therefore a 
regulation of GAR22 by cdk5 in neuronal cells may function to regulate axon 
outgrowth. It would be interesting to explore, whether cdk5 co-localizes with 
GAR22 and how the potential regulation of GAR22 by cdk5 plays a role in 
axon outgrowth decisions and axon guidance.  
EB1 is found at the microtubule ends throughout extending neurites 
(Morrison et al., 2002). In addition, it was shown that APC in neurons 
localizes only at the tip of the neurite, which will be the future axon (Votin et 
al., 2005). EB1 can mediate the binding of APC to microtubules, where it 
stabilizes them and has a role in directed cell migration (Nathke et al., 1996; 
Zumbrunn et al., 2001). But with binding of EB1 to GAR22, it might be 
possible that the interaction of APC to EB1 is inhibited. Neurons 
overexpressing GAR22 showed reduced axon outgrowth indicating a 
regulating role for GAR22 on EB1 and microtubule dynamics. It is thus 
tempting to hypothesize that GAR22 suppresses axon outgrowth by binding 
EB1, possibly by blocking APC-EB1 interaction. This would lead to unstable 
microtubules on sites in the neuron where neurites should not develop to an 
axon. On the other hand, the neurite, which will become an axon, has 
stabilized microtubules with APC and EB1 bound at the plus end tips. A 
more detailed analysis of the exact localization of GAR22 could give insights in 
this hypothesis. 
As discussed above, GAR22 was identified as a potential tumor suppressor 
(Zucman-Rossi et al., 1996), EB1, on the other hand, was described as an 
oncoprotein (Liu et al., 2009) and its expression is controlled by c-Myc (Orimo 
et al., 2008). The potential tumor suppressor activity of GAR22 could 
therefore function by inhibiting the oncogenic activity of EB1. Additionally, as 
demonstrated above, overexpression of GAR22 can delay cell cycle progression. 
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It might be proposed that the tumor suppressor activity of GAR22 act on 
microtubule stability and dynamics via EB1 during mitosis thereby regulating 
proliferation. Since GAR22 is encoded in a part of chromosome 22, which is 
often deleted in different tumor types (Zucman-Rossi et al., 1996), it would be 
of great interest to analyze the impact of ectopic GAR22 on tumor cells 
lacking endogenous GAR22 expression.  
In summary, GAR22 could function to fine-tune the binding of EB1 to 
microtubule plus ends and locally influencing microtubule stability. As a 
consequence, GAR22 may take part in determining the direction of migrating 
cells. The CH and GAR domains would contribute to the proper sub-cellular 
localization of GAR22, which may participate to the regulation of the 
interplay between the actin and microtubule cytoskeleton also at structural 
level.  
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6.2 Abbreviations 
7AAD 7-amino-actinomycin D 
9cRA 9-cis-retinioc acid 
AGM aorta-gonad-mesonephros 
ALAD delta-aminolevulinate dehydratase 
APC adenomatous polyposis coli 
Arp2/3 actin related protein 
BFU-E burst forming unit-erythroid 
BrdU Bromodeoxyuridine 
BSA bovine serum albumin 
BTEB1 basic transcription binding protein 1/ Krüppel-like factor 
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CD cluster of differentiation 
cdk cyclin dependent kinase 
CFU-E colony forming unit-erythroid 
CH calponin homologue  
CLASP CLIP associated protein 
CLIP CAP-Gly domain containing linker protein 
DAPI 4′,6-Diamidino-2-phenylindole dihydrochloride 
Dex dexamethasone 
DMEM Dulbecco’s modified Eagle’s medium 
DNA deoxyribonucleic acid 
DTT DL-Dithiothreitol 
EB1 end binding protein 1 
EDTA Ethylenediaminetetraacetic acid 
EGTA Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid 
EKLF erythroid krüppel-like factor 
Epo erythropoietin  
F-actin filamentous actin 
FAK focal adhesion kinase 
f.c. final concentration 
FITC Fluorescein isothiocyanate isomer 
GAR22 GAS2 related gene on chromosome 22 
Gas2 growth arrest specific gene 2 
GATA-1 GATA-binding protein 1 (globin transcription factor 1) 
GATA-2 GATA-binding protein 2 
GEO gene expression omnibus 
GFP green fluorescent protein 
GST glutathione S-transferase 
GSH glutathione  
HCl hydrochloride acid 
HDAC histone deacetylase  
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HSC hematopoietic stem cell 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
kDa kilo Dalton 
APPENDIX  117 
 
LB Luria-Bertani 
LMO2 LIM kinase only 2 
MACF microtubule-actin crosslinking factor 
MAP microtubule associate protein 
MTOC microtubule-organizing center 
mRNA messenger ribonucleic acid 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PE R-Phycoerythrin 
Pen/Strep Penicillin/Streptavidin 
PFA para-formaldehyde 
PI propidium iodide  
PI3K phosphatidylinositol 3-kinase 
PIPES 1,4-Piperazinediethanesulfonic acid 
PMSF Phenylmethanesulfonyl fluoride 
RNA ribonucleic acid 
RXR retinoid X receptor 
SDS sodium dodecyl phosphate 
SDS-PAGE SDS-polyacrylamid-gelelectrophorese 
SCF stem cell factor 
T3 3,5,3’triiodo-L-thyronine, thyroid hormone 
TEMED N,N,N′,N′-Tetramethylethylenediamine 
+TIPs plus end tracking protein  
TR thyroid hormone receptor 
TAP tandem affinity purification 
TBS Tris based saline 
U Unit 
WT wild type 
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6.3 Vector maps 
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